

Final Programme

GLASGOW 2014



94<sup>th</sup> Annual Meeting

The British Association of Dermatologists

SECC, Glasgow 1<sup>st</sup> – 3<sup>rd</sup> July 2014



# PSORIASIS

## FROM GENE TO CLINIC

7th International Congress

The Royal College of Physicians, London, UK  
11th-13th December 2014

Organised by Conference and Events Services  
of The British Association of Dermatologists  
under the auspices of St. John's Institute of Dermatology,  
Kings College London and the Dermatology Centre,  
University of Manchester

Please put the date in your diary!



The University of Manchester



### CO-ORGANISERS

Jonathan Barker London, UK  
Christopher Griffiths Manchester, UK

### SCIENTIFIC COMMITTEE

Hervé Bachelez Paris, France  
James Elder Ann Arbor, USA  
Alexa Kimball Boston, USA  
James Krueger New York, USA  
Alan Menter Dallas, USA  
Frank Nestle London, UK  
Errol Prens Rotterdam, The Netherlands  
Jörg Prinz Munich, Germany  
Peter Van de Kerkhof Nijmegen, The Netherlands

### PROGRAMME

The programme will concentrate on key issues relating to psoriasis at both scientific and clinical levels. There will be keynote and invited lecturers present. Plenary sessions will cover the following topics:

- Genetics
- Immunology and immunity
- Co-morbidities and outcome measures
- Targeted therapeutics

For further information please contact:  
Organising Secretariat

Conference and Event Services  
British Association of Dermatologists  
4 Fitzroy Square, London W1T 5HQ

Tel: +44 (0)20 7391 6358 Fax: +44 (0)20 7388 0487

Email: [conference@bad.org.uk](mailto:conference@bad.org.uk)

Website: [www.psoriasisg2c.com](http://www.psoriasisg2c.com)

**Overview**

App	70
Badges	7
Banking	7
Business Services	7
Catering	7
Certificates of attendance	7
Cloakroom	7
Committee meetings	11
Continuing Professional Development (CPD)	7
Exhibition	7
Exhibition quiz	7
Exhibition Plan	60
Exhibitor Directory	62-66
First aid	7
Focus Sessions	55
Hot Topics Overview	58
Map of Glasgow	67
Meetings Calendar	68
Organising Committees	4
Parking	7
Patient support groups	61
Payment of registration fees	7
Poster exhibition	7
Posters	56-57
Programme Overview	6
Registration desk	7
Satellite Symposia	7
Social events	10
Speaker preview	7
Venue Plan	8-9
Welcome to Glasgow	5
Wi-Fi	7

**Monday 30th June Overview 12**

BSD Self-Assessment	13
Trainee pre-conference session	14
SAS Session	15

**Tuesday 1st July Overview 16**

CPCs - Joint BAD / BSD	17
British Society of Cutaneous Allergy (BSCA)	18-19
BADGEM	20
British Society for Dermatological Surgery (BSDS)	21-23
Senior Skin Group	24
British Society for Dermatopathology (BSD)	26-27
Plenary Session – Submitted papers	28
Dermatology Teachers	29

**Wednesday 2nd July Overview 32**

Plenary session – Understanding Pharma	35
Historical	36
Commonwealth Session	37
British Teledermatology Society (BTS)	38
Public Session - Dermatology Question Time	39
Plenary session - Medical Dermatology	43
British Society for Paediatric Dermatology (BSPD)	44-45
BAD and BDNG Joint Meeting	46

**Thursday 3rd July Overview 47**

Plenary Session Professors & Registrars forum	48
British Photodermatology Group (BPG)	49-50
British Society for Skin Care In Immunocompromised Individuals (BSSCII)	52-53
CPD update	54
Focus Sessions	55

**Keynote Lectures**

<b>Tuesday</b>	
Professor Amrinder J Kanwar	28
Professor Robert Moots	28
<b>Wednesday</b>	
Professor Sir Ian Kennedy	35
<b>Thursday</b>	
Dr Rachael Clark	54
Professor Vinod Sharma	54

**CONFERENCE & EVENT SERVICES**

Mr Chris Garrett - Conference & Event Services Manager  
 Mrs Jenna Bowler – Senior Events Coordinator  
 Mrs Marie Elwér – Finance and Conference Administrator  
 Miss Sally-Ann Koomson – Marketing & Events Coordinator  
 Miss Sophie Jackson – Events Coordinator

**ORGANISING COMMITTEE**

Dr Khadija Al Jefri  
 Miss Marilyn Benham  
 Mrs Jenna Bowler  
 Dr David Brass  
 Prof Chris Bunker  
 Dr David J Eedy  
 Mr Chris Garrett  
 Mrs Catherine Hanaway  
 Prof Eugene Healy  
 Dr Glenda Hill  
 Prof Irene Leigh  
 Dr Anshoo Sahota  
 Dr Graham Sharpe - Chair

**BAD ABSTRACT SELECTION COMMITTEE**

Dr Thomas Brenn  
 Dr Eduardo Calonje  
 Dr Paul Craig  
 Prof Eugene Healy  
 Dr Walayat Hussain  
 Prof Irene Leigh  
 Dr Catherine Orteu  
 Dr Manuraj Singh  
 Dr Helen Young

**BAD JUDGING COMMITTEE**

Dr Elaine Agius  
 Dr Allison Bedlow  
 Dr Emma Benton  
 Dr Chris Bower  
 Dr Sara Brown  
 Dr Ophelia Dadzie  
 Dr Judith Ellison  
 Dr Hiva Fassihi  
 Dr Carsten Flohr  
 Dr Claire Fuller  
 Dr Mark Griffiths  
 Dr Muzlifah Haniffa  
 Dr Sandy McBride  
 Dr Susie Morris  
 Dr Catherine Orteu – Chair  
 Dr Neil Rajan  
 Dr Manuraj Singh  
 Dr Victoria Swale

**BPG ABSTRACT SELECTION COMMITTEE**

Dr Richard Dawe  
 Dr Chris Edwards  
 Dr Hiva Fassihi  
 Prof James Ferguson  
 Dr Victoria Goulden  
 Dr Ljubomir Novakovic  
 Dr Robert Sarkany

**BSCA ABSTRACT SELECTION COMMITTEE**

Dr Donna Thompson  
 Dr Sarah Wakelin  
 Dr Mark Wilkinson

**BSPD ABSTRACT SELECTION COMMITTEE**

Dr Paula Beattie  
 Dr Fiona Browne  
 Dr Jane Ravenscroft

**BSD ABSTRACT SELECTION COMMITTEE**

Dr Thomas Brenn  
 Dr Eduardo Calonje  
 Dr Paul Craig  
 Dr Manuraj Singh

**BSDS & BCDG ABSTRACT SELECTION COMMITTEE**

Dr Chris Bower  
 Dr Vindy Ghura  
 Dr Wal Hussain  
 Dr Stephen Keohane  
 Dr Nick Lowe

**BSSCII ABSTRACT SELECTION COMMITTEE**

Prof Catherine Harwood  
 Dr John Lear  
 Dr David Paige  
 Dr William Phillips  
 Prof Charlotte Proby  
 Dr Helen Ramsay

**BTS ABSTRACT SELECTION COMMITTEE**

Dr Carolyn Charman  
 Dr David de Berker  
 Dr Saul Halpern  
 Dr Andy MacFarlane  
 Dr Colin Morton

**DERMATOLOGY TEACHERS SELECTION COMMITTEE**

Dr Stuart Cohen  
 Dr Shaheen Haque  
 Dr Jon Goulding  
 Dr Gayathri Perera  
 Dr Minal Singh

**HISTORICAL ABSTRACT SELECTION COMMITTEE**

Dr Peter Copeman  
 Dr David Eedy  
 Dr Julia Ellis  
 Dr Frances Humphreys  
 Dr Nick Levell  
 Dr Sid Orpin  
 Dr Rakesh Patalay  
 Dr Paul Yesudian

**ACKNOWLEDGEMENTS**

The British Association of Dermatologists gratefully acknowledges the contribution of the many exhibitors & sponsors whose attendance has helped make the meeting possible.



**W**elcome to Glasgow and the 94th Annual Meeting of the British Association of Dermatologists. We are once again delighted to be in the award winning Scottish Exhibition & Conference Centre.

Glasgow is a city with everything to offer. It is Scotland's cultural capital and one of the most dynamic cities in Europe: steeped in culture, rich in history, with elegant streets, squares, parks and gardens; the name Glasgow actually means 'dear green place'. What's more, it's one of the UK's finest Victorian cities with magnificent architecture everywhere you look. The respected Lonely Planet guide recently said of the city: "Glasgow is regenerating and evolving at a dizzying pace. Its Victorian architectural legacy is now swamped with cutting-edge style bars and world-class venues to tickle your taste buds. The city is going through a long-term transformation, evident along the revitalised River Clyde."



## SCIENTIFIC PROGRAMME

Building on its reputation as a high quality internationally renowned event, the BAD Conference and Events committee has again worked hard to provide a blend of new scientific presentations with updates from experts in various fields. We are pleased that the Arthur Rook Oration will be delivered by Dr Rachael Clark from Boston, USA. Professor Robert Moots from Liverpool and Professor Amrinder Kanwar from India will give the first of the guest lectures at the plenary session on Tuesday speaking on 'Behçet's Syndrome: a new approach' and 'Vitiligo-an Indian perspective' respectively. Wednesday's programme features Professor Sir Ian Kennedy who will update the BAD membership on Professional Regulation. The final guest lecture will come from Professor Vinod Sharma, who will talk during the CPD session on Thursday afternoon speaking on 'The Dark Skin and Photodermatoses'.

We have a new Commonwealth session on Wednesday morning and following feedback from the 2013 evaluation we have spread the Special Interest Groups to offer a better balance to the three days. Please also look out for the new 'Hot topics' within the Exhibition Hall.

Those attendees not participating in the AGM on Wednesday are encouraged to register for the 'Dermatology Question Time' hosted by Martyn Lewis. Please visit the on-site registration desk as numbers are limited.

On Monday 30th June we will be holding pre-conference sessions for trainees, Specialty & Associate Specialist doctors, medical students and there will be a BSD self assessment session.

Socially, the Annual Dinner will be at the Kelvingrove Museum on Wednesday evening, with a Welcome Reception in the Glasgow Science Centre on the Tuesday evening.

This year's meeting will have an International feel with attendees from India, Sri Lanka, Canada, USA and China.

We offer a warm welcome to all delegates and hope you enjoy the meeting!

A handwritten signature in black ink that reads "G. R. Sharpe". The signature is written in a cursive, flowing style.

**Dr Graham Sharpe**  
*Clinical Vice President (2012-2014)*

# Programme Overview

## MONDAY 30 JUNE 2014

TIME	SESSION DETAIL	ROOM	INFORMATION
12:15 – 18:00	Trainee Pre-conference Session	Lomond	Page 14
12:15 – 17:35	Speciality & Associate Specialist Session	Leven	Page 15
12:45 – 18:15	BSD Self-Assessment	Carron	Page 13

## TUESDAY 1 JULY 2014

TIME	SESSION DETAIL	ROOM	INFORMATION
08:30 – 12:45	British Society of Cutaneous Allergy	Boisdale	Page 18-19
09:00 – 12:10	Clinicopathological Cases	Lomond	Page 17
09:00 – 13:00	BADGEM	Dochart 2	Page 20
10:45 – 11:15	Hot Topics	Exhibition	Page 58
11:15 – 17:30	British Society for Dermatological Surgery	Alsh	Page 21-23
12:30 – 14:00	Senior Skin Group	Dochart 1	Page 24
14:00 – 14:15	Opening Address	Lomond	Page 28
14:00 – 17:30	British Society for Dermatopathology	Boisdale	Page 26-27
14:15 – 14:45	Guest Lecturer: Professor Amrinder J Kanwar	Lomond	Page 28
14:45 – 17:30	Plenary Session – Submitted Papers	Lomond	Page 28
15:45 – 16:15	Hot Topics	Exhibition	Page 58
16:30 – 17:30	Dermatology Teachers	Dochart 1	Page 29
17:30 – 18:00	Guest Lecturer: Professor Robert Moots	Lomond	Page 28
18:00 – 20:00	Welcome Reception	Glasgow Science Centre	Page 10

## WEDNESDAY 2 JULY 2014

TIME	SESSION DETAIL	ROOM	INFORMATION
08:00 – 08:45	Novartis Sponsored Symposium	Alsh	Page 33
08:00 – 08:45	Celgene Sponsored Symposium	Boisdale	Page 34
08:45 – 10:15	Plenary session – Understanding Pharma	Lomond	Page 35
08:45 – 10:45	Historical	Carron	Page 36
08:45 – 10:15	Commonwealth Session	Dochart	Page 37
08:45 – 10:15	British Teledermatology Society	Leven	Page 38
10:15 – 10:45	Guest Lecturer: Professor Sir Ian Kennedy	Lomond	Page 35
11:15 – 13:00	AGM – BAD members only	Lomond	
11:30 – 12:30	Public Session - Dermatology Question Time	Alsh	Page 39
13:15 – 14:15	Novartis Sponsored Symposium	Boisdale	Page 40
13:15 – 14:15	Roche Sponsored Symposium	Carron	Page 41
13:15 – 14:15	Leo Pharma Sponsored Symposium	Dochart	Page 42
14:30 – 17:50	Plenary session - Medical Dermatology and Submitted Papers	Lomond	Page 43
14:30 – 18:00	British Society for Paediatric Dermatology	Alsh	Page 44-45
15:30 – 18:00	BAD and BDNG Joint Meeting	Boisdale	Page 46
16:15 – 16:45	Hot Topics	Exhibition	Page 58
19:30 – 00:00	Annual Dinner	Kelvingrove Museum	Page 10

## THURSDAY 3 JULY 2014

TIME	SESSION DETAIL	ROOM	INFORMATION
07:30 – 08:30	Christian Medical Fellowship Breakfast	Ness	
08:45 – 12:40	Plenary Session Professors & Registrars forum	Lomond	Page 48
08:45 – 12:45	British Photodermatology Group	Alsh	Page 49-50
08:50 – 12:30	British Society for Skin Care in Immunocompromised Individuals	Carron	Page 52-53
13:30 – 14:15	Arthur Rook Oration: Dr Rachael Clark	Lomond	Page 54
14:15 – 17:00	CPD update	Lomond	Page 54
15:00 – 15:30	Focus Session - Alopecia	Alsh	Page 55
15:00 – 15:30	Focus Session - Itch	Boisdale	Page 55
15:00 – 15:30	Focus Session - Hyperhidrosis	Carron	Page 55
15:30 – 16:00	Guest Lecturer: Professor Vinod Sharma	Lomond	Page 54

## APP

We are pleased to announce that we will be providing a smartphone conference app for delegates to use during the conference.

The app will provide the following features;

- Review agenda & speakers
- View sponsors & exhibitors
- Interactive floorplans
- Select sessions to record your own CPD
- View abstracts & e-posters

BAD 2014 is grateful to Janssen for sponsoring this app.



## BADGES

Conference badges will be handed to delegates on registration. For security purposes name badges must be worn at all times throughout the meeting. In the event that you lose your badge, a replacement must be obtained at the registration desk immediately.

## BANKING

ATM facilities are available on the SECC complex.

## BUSINESS SERVICES

The SECC has a well equipped Information & Business Centre for visitors. Available services include:

PC Use/Internet Access	Scanning
Photocopying	Faxing
Printing	Gift Shop

## CATERING

Lunch and all scheduled refreshment breaks will be served from designated points in the exhibition area, Hall 5 of the SECC.

Each lunch ticket will entitle you to one choice of lunch offered at the various catering pods. Additional lunch items can be purchased on a cash basis.

## CERTIFICATE OF ATTENDANCE

Certificates of attendance will be in your registration envelope.

## CLOAKROOM

There is a cloakroom located on the main concourse. There is a charge of £2 per item. Guests will also be able to store luggage on the day of departure

## CONTINUING PROFESSIONAL DEVELOPMENT CREDITS (CPD)

This event is approved for external credit for the CPD scheme of the Federation of Royal Colleges of Physicians of the UK. Physicians should record their credits in their diaries, in accordance with the current RCP recommendations. Participants should only record the number of hours they attended. The main meeting has been approved for 18 credits and the CPD code is 89886.

## EXHIBITION

The exhibition will be located in Hall 5 of the SECC and will be open at the following times:

Tuesday 1st July:	10:00 – 17:30	Thursday 3rd July:	08:30 – 14:00
Wednesday 2nd July:	08:30 – 17:30		

## EXHIBITION QUIZ

Exhibition quiz forms will be included in the delegate bags. To participate in the quiz, delegates must visit each participating exhibitor and answer a simple question. Participants must also obtain four answers from the patient support groups, please note you only need four from any of the patient support groups present over the duration of the meeting. All completed quiz forms must be returned to the registration desk by 14:00 on Thursday 3rd July. The prizes will be announced after the meeting.

## FIRST AID

The well equipped Medical Centre is located on the concourse of the main building, at the East entrance.

## PARKING

The nearest car park to the SECC is the multi-storey car park operated by City Parking (Glasgow) LLP. The car park is open 24 hours a day. The facility is located at 10 Stobcross Road, Glasgow, G3 8YW.

## PAYMENT OF REGISTRATION FEES

We would prefer delegates to pay by cheque (pounds sterling drawn on a UK bank only or by sterling bank draft) made payable to the 'British Association of Dermatologists'. Cheques in other currencies cannot be accepted. Alternatively, delegates may pay by credit card and this is encouraged for overseas delegates. Please note that we only accept MasterCard and Visa. American Express cannot be accepted.

## POSTER EXHIBITION

The poster exhibition will be located within the exhibition hall. The posters will be numbered and a list is provided at the back of this programme.

There will be an e-poster display area showing all the posters submitted. Posters should be removed by 14:00 on Thursday 3rd July. Please note that the British Association of Dermatologists cannot be held responsible for any loss or damage to a poster presented during the Annual Meeting.

## REGISTRATION DESK

The registration desk will be located in the entrance to the exhibition and will be staffed by the BAD team during the following hours:

Monday 30th June	09:00 – 18:00
Tuesday 1st - Thursday 3rd July	08:00 – 18:00

## SATELLITE SYMPOSIA

The following companies will be holding satellite symposia at the meeting:

Wednesday 2nd July

08:00 – 08:45	Alsh	Novartis
08:00 – 08:45	Boisdale	Celgene
13:15 – 14:15	Boisdale	Novartis
13:15 – 14:15	Dochart	Leo Pharma
13:15 – 14:15	Carron	Roche

## SPEAKER PREVIEW

Speaker preview will be located in the Etive in the Lomond Suite, please ask at the registration desk for directions. All presenters must take their memory sticks to speaker preview at least two hours prior to their presentation. Data projection (PowerPoint) will be available.

## TAXIS

There is a taxis rank pick-up and drop-off point at the East entrance adjacent to the Clyde Auditorium.

## VENUE

Scottish Exhibition & Conference Centre (SECC)  
Exhibition Way, Glasgow G3 8YW

Tel: 0141 248 3000 Email: [info@secc.co.uk](mailto:info@secc.co.uk) [www.secc.co.uk](http://www.secc.co.uk)


## HOW TO ACCESS THE Wi-Fi

There is Wi-Fi access throughout the SECC.


Please search Wi-Fi on your device and select the wireless network 'SECC Wi-Fi'. Please enter the below username and password to be automatically connected.

Username – BAD2014  
Password – BAD2014

# Venue Plan







## Social Events

### WELCOME RECEPTION

**1 July 2014, The Glasgow Science Centre  
18:00 - 20:00**

The Welcome Reception will be held at the Glasgow Science Centre, situated in the heart of Glasgow on the banks of the River Clyde. Striking with its titanium clad structures; it features the Science Mall as well as the IMAX theatre.

The centre aims to showcase Scotland's contribution to science and technology, past, present and future. The Glasgow Science Centre is a five minute walk from the SECC across the River Clyde.

Drinks and canapés will be served and all registered delegates are invited to attend the Welcome Reception



### ANNUAL DINNER

**2 July 2014, Kelvingrove Art Gallery  
and Museum  
19:30 – 00:00**

The Annual Dinner will be held at the Kelvingrove Art Gallery and Museum, a striking building in the beautiful surroundings of Kelvingrove Park.

Kelvingrove Art Gallery and Museum houses one of Europe's great art collections. It is amongst the top three free to enter visitor attractions in Scotland and one of the most visited museums in the United Kingdom outside of London.

A Ceilidh – a Scottish dance with a traditional band will be held prior to the disco. Learn new dance steps with help from the band caller!



# Committee Meetings

## MONDAY 30 JUNE 2014

TIME	MEETING DETAIL	ROOM
10:30 – 16:00	BJD Editorial Team Meeting	Ness
11:00 – 13:00	SAS Sub-committee	Fyne
16:00 – 18:00	British Association of Dermatologists Officers	Fyne
18:30 – 19:30	National Dermatology Trainee Committee	Dochart 2

## TUESDAY 1 JULY 2014

TIME	MEETING DETAIL	ROOM
08:00 – 09:00	British Society for Dermatopathology Exec Committee	Fyne
08:30 – 10:30	British Skin Foundation Grants Advisory	Morar
08:30 – 09:30	The British Society of Cutaneous Allergy (BSCA) AGM	Boisdale
09:30 – 10:30	BAD Finance Meeting	Ness
11:15 – 13:00	Dermatology Industry Group	Morar
12:00 – 14:00	Community Dermatology Editorial Board Meeting	Ness
13:00 – 14:00	British Cosmetic Dermatology Group AGM	Carron 1
13:30 – 15:30	BADGEM Clinical Trials sub-group meeting	Katrine
14:00 – 14:30	British Society for Dermatopathology AGM	Boisdale
14:00 – 15:30	Teachers of Undergraduate Dermatology	Leven
14:00 – 15:30	Health Informatics Sub-committee	Morar
14:00 – 16:00	The British Society of Cutaneous Allergy Committee	Fyne
14:30 – 16:30	BADGEM Informatics sub-group meeting	Dochart 2
16:00 – 17:00	Therapy & Guidelines Sub-committee	Morar
16:00 – 17:30	Specialised Dermatology CRG meeting	Carron 2
17:05 – 17:30	British Society for Dermatological Surgery AGM	Alsh

## WEDNESDAY 2 JULY 2014

TIME	MEETING DETAIL	ROOM
08:00 – 09:00	Skin Cancer Prevention Sub-committee meeting	Ness
08:00 – 09:00	BJD Editorial Board Meeting	Morar
08:30 – 11:00	British Society for Dermatological Surgery Committee	Katrine
09:30 – 11:00	British Society for Paediatric Dermatology Training Committee	Fyne
10:00 – 10:15	British Teledermatology Society AGM	Leven
10:45 – 11:15	Historical Collection Sub-Committee	Carron
11:15 – 13:00	British Association of Dermatologists AGM (Members Only)	Lomond
13:00 – 14:00	British Association of Dermatologists Officers	Katrine
13:15 – 14:15	British Society for Paediatric Dermatology Committee	Morar
14:15 – 15:15	British Association of Dermatologists Executive Committee	Leven
17:00 – 18:00	UK DCTN Trial Prioritisation Panel	Katrine
18:00 – 19:00	British Society for Medical Dermatology Committee	Ness

## THURSDAY 3 JULY 2014

TIME	MEETING DETAIL	ROOM
08:30 – 09:30	Exhibitors' Meeting	Leven
11:30 – 13:00	UK Dermatology Clinical Trials Network AGM	Ness
12:05 – 12:30	British Society for Skin Care in Immunocompromised Individuals AGM	Carron
12:15 – 12:45	British Photodermatology Group AGM	Alsh
12:30 – 13:30	British Epidermo-Epidemiology Society AGM	Fyne
13:00 – 14:30	World Congress on Cancers of the Skin 2014 Programme Committee	Leven
14:30 – 15:30	World Congress on Cancers of the Skin 2014 LOC	Leven
15:00 – 16:30	British Photodermatology Group Committee	Katrine

# Monday 30 June Overview

## MONDAY 30 JUNE 2014

TIME	SESSION DETAIL	ROOM	INFORMATION
12:15 – 18:00	Trainee Pre-conference Session	Lomond	Page 14
12:15 – 17:35	Speciality & Associate Specialist Session	Leven	Page 15
12:45 – 18:15	BSD Self-Assessment	Carron	Page 13

Mon 30 June





# Trainee Session

**Date:** Monday 30th June  
**Time:** 12:15-18:00  
**Room:** Lomond  
**Chair:** Dr Khadija Al-Jefri and Dr David de Berker

Mon 30 June

PROGRAMME		
12:15 – 12:55	Lunch	Boisdale Room
12:55 – 13:00		<b>Welcome and Introduction</b> Dr Khadija Al-Jefri and Dr David de Berker
13:00 – 13:30	TPC01	<b>Allergy and Patch testing</b> Dr Jonathan White
13:30 – 14:00	TPC02	<b>Skin surgery- common skin flaps</b> Dr Tom Oliphant
14:00 – 14:30	TPC03	<b>Dermatology in the immunocompromised</b> Prof Charlotte Proby
14:30 – 15:00	TPC04	<b>Cases from the Paediatric Dermatology Clinic</b> Dr Hossain Shahidullah
15:00 – 15:30	TPC05	<b>Topical photodynamic therapy in dermatology</b> Dr Sally Ibbotson
15:30 – 15:40	TPC06	<b>Update on trainee issues</b> Dr Khadija Aljefri
15:40 – 16:00	Break	Boisdale Room
16:00 – 16:30	TPC07	<b>Medicolegal cases in dermatology/Medicolegal guidance</b> Dr Jane McGregor
16:30 – 17:00	TPC08	<b>Introduction to teledermatology</b> Dr David de Berker
17:00 – 17:30	TPC09	<b>Vulval dermatoses</b> Dr Janet McLelland
17:30 – 18:00	TPC10	<b>Porter’s Penile Pearls</b> Dr Bill Porter
18:00	TPC11	Quiz
18:00 – 21:00		Trainee evening event @ Clyde Built

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

# Speciality & Associate Specialists Session

**Date:** Monday 30th June  
**Time:** 12:15-17:35  
**Room:** Leven  
**Chair:** Dr Inma Mauri-Sole

Mon 30 June

PROGRAMME		
12:15 – 13:00	Lunch	Morar Room
13:00 – 13:05		<b>Welcome and Introduction</b> Dr Glenda Hill
13:05 – 13:45	SAS01	<b>All you need to know to manage Darier’s &amp; Hailey-Hailey Disease</b> Dr Ruth Murphy
13:45 – 14:25	SAS02	<b>Assessment &amp; categorisation of skin wounds-how I manage them</b> Dr Catriona Wootton
14:25 – 15:05	SAS03	<b>Recent developments in Neurofibromatosis relevant to dermatology</b> Dr Emma Burkitt-Wright
15:05 – 15:35	Break	Morar Room
15:35 – 16:15	SAS04	<b>Lumps &amp; Bumps in Paediatric dermatology-safe or scary?</b> Dr Olivia Schofield
16:15 – 16:55	SAS05	<b>Graft vs Host Disease- focusing on cutaneous manifestations</b> Dr Fiona Child
16:55 – 17:35	SAS06	<b>Isolated limb perfusion or ECT for malignant Melanoma-an overview</b> Dr Jerry Marsden
17:35		Closing Remarks
19:30 – 22:00		SAS evening event @ La Rotunda (pre-booked only)

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

# Tuesday 1 July Overview

## TUESDAY 1 JULY 2014

TIME	SESSION DETAIL	ROOM	INFORMATION
08:30 – 12:45	British Society of Cutaneous Allergy	Boisdale	Page 18-19
09:00 – 12:10	Clinicopathological Cases	Lomond	Page 17
09:00 – 13:00	BADGEM	Dochart 2	Page 20
10:45 – 11:15	Hot Topics	Exhibition	Page 58
11:15 – 17:30	British Society for Dermatological Surgery	Alsh	Page 21-23
12:30 – 14:00	Senior Skin Group	Dochart 1	Page 24
14:00 – 14:15	Opening Address	Lomond	Page 28
14:00 – 17:30	British Society for Dermatopathology	Boisdale	Page 26-27
14:15 – 14:45	Guest Lecturer: Professor Amrinder J Kanwar	Lomond	Page 28
14:45 – 17:30	Plenary Session – Submitted Papers	Lomond	Page 28
15:45 – 16:15	Hot Topics	Exhibition	Page 58
16:30 – 17:30	Dermatology Teachers	Dochart 1	Page 29
17:30 – 18:00	Guest Lecturer: Professor Robert Moots	Lomond	Page 28
18:00 – 20:00	Welcome Reception	Glasgow Science Centre	Page 10

Tue 1 July





# Clinicopathological Cases

**Date:** Tuesday 1st July  
**Time:** 09:00-12:10  
**Room:** Lomond  
**Chair:** Dr Thomas Brenn & Dr Manuraj Singh  
 Dr Eduardo Calonje & Dr Paul Craig

PROGRAMME		
09:00 – 09:07	CPC03	<b>Urticarial dermatitis: a presenting feature of lymphoma or just a variant of Schnitzler's syndrome?</b> F.R. Ali, L. Motta, A. Bloor and A.M. Marsland
09:07 – 09:14	CPC02	<b>Lymphomatoid plaquosis- a novel cutaneous CD30+ T-cell lymphoma spontaneously resolving and recurring on the same skin sites</b> C. Haddadeen, C. Lai, S-Y. Cho, A. Fityan, A. Bates, J. Theaker and E. Healy
09:14 – 09:21	CPC01	<b>Erythema gyratum repens-like vasculitis</b> N. Spierings and J. Natkunarajah
09:21 – 09:28	CPC04	<b>Mesenteric cysts in Gorlin syndrome: a mimic of metastatic disease</b> N. Rajan, S. Brown, S. Ward, P. Pieniazek, P. Hainsworth, F. Douglas, A. Husain and R. Plummer
09:28 – 09:35	CPC05	<b>Symmetrical Idiopathic MicroPapular Facial Eruption or SIMPLE – a case series describing a new, distinct clinical entity characterised by lichen planopilaris affecting vellus hairs in the absence of frontal fibrosing alopecia</b> J. Newsham, L. Motta, L.A. Jamieson and V. Madan
09:35 – 10:20		Joint BAD/BSA Neil Smith Lecture <b>Pitfalls and Controversies in Mesenchymal Tumours of the Skin</b> <i>Professor Christopher Fletcher (Boston, USA)</i> The practice of pathology (including dermatopathology) is replete with surprisingly numerous examples of unreliable dogma, outdated falsehoods, unsubstantiated claims and 'lore' handed down over decades. Many of these misconceptions are perpetuated informally and are hard to dislodge. This talk will aim to address a selection of these issues.
10:20 – 11:00	Break	Exhibition Hall 5
11:00 – 11:07	CPC06	<b>A rare case of cutaneous collagenous vasculopathy</b> N. Meah, J. Ellison and N. Khirwadkar
11:07 – 11:14	CPC07	<b>Adult-onset pansclerotic morphea</b> S. Aryiku and W. Perkins
11:14 – 11:21	CPC08	<b>Beware of scrotal ulceration during induction chemotherapy with all-trans retinoic acid</b> C. Foley and P. Marren
11:21 – 11:28	CPC09	<b>Xanthoma disseminatum in a patient with B-cell acute lymphoblastic leukaemia</b> V.M. Smith, R. Rose and W. Merchant
11:28 – 11:35	CPC10	<b>Fat necrosis secondary to a deficiency in protein C and antithrombin</b> C. Edwards, E. Agius, V. Akhras and J. Uprichard
11:35 – 11:42	CPC11	<b>Periorbital and perioral oedema: an unreported presentation of reactive haemophagocytic lymphocytosis</b> T.N. Shim, S.D. Orpin and T.M. Finch
11:42 – 11:49	CPC12	<b>Subacute cutaneous lupus erythematosus occurring post-radiotherapy</b> D.Y.L. Tang, S. Whitaker and S. Wahie
11:49 – 11:56	CPC13	<b>Suppurative variant of childhood periorificial granulomatous dermatitis</b> A. Kapadia and S. Attili
11:56 – 12:03	CPC14	<b>A case of suspected human-to-human transmission of orf between mother and child</b> V. Rajkomar, M. Hannah, I. Coulson and C. Owen
12:03 – 12:10	CPC15	<b>Trichodysplasia spinulosa-associated polyomavirus: a rare cutaneous complication following renal transplantation</b> F.R. Ali, A. Aslam, L. Motta and J.T. Lear

Tue 1 July

# British Society for Cutaneous Allergy

**Date:** Tuesday 1st July  
**Time:** 08:30-12:45  
**Room:** Boisdale  
**Chair:** Dr David Orton & Dr Donna Thompson  
 Dr Sarah Wakelin & Dr Mark Wilkinson

Tue 1 July

PROGRAMME		
08:30 – 09:00		AGM
09:00 – 09:30		<p>Prosser White Oration  <b>Patch testing in the investigation of non-immediate drug eruptions</b>  <i>Dr Margarida Goncalo</i></p> <p>Patch testing with systemic drugs is increasingly being used in the study of drug eruptions (DE), both for reinforcing a clinical drug imputation and for the study of pathomechanisms and cross-reactions. Patch tests (PT) with pure drugs give highly specific results, but often it is necessary to use commercial drugs used by the patients for which specificity is more variable. Sensitivity depends both on the clinical pattern of DE and on the responsible drug. Positive reactions occur mainly in delayed maculopapular eruptions, DRESS, acute generalized exanthematous pustulosis and fixed drug eruptions (FDE), in the latter only at lesional skin and usually within 24h. Carbamazepine, tetrazepam, diltiazem, abacavir, aminopenicillins and clindamycin induce positive PT reactions in 30-70% of cases. Negative PT are the rule for allopurinol. A positive skin test is important to confirm the culprit drug in a DE, whereas a negative PT does not exclude a probable drug imputation, but can suggest alternative drugs to challenge patients. PT can help us understand the physiopathology of DE as they often reproduce the clinical and histological pattern of the DE.</p>
09:30 – 09:40	CD01	<b>Occupational exposure to propranolol: an unusual cause of allergic contact dermatitis</b> F.R. Ali, D.B. Shackleton, T.P. Kingston and J.D.L. Williams
09:40 – 09:50	CD02	<b>What is the relevance of contact allergy to sodium metabisulfite and which concentration of the allergen should we use?</b> N. Ralph, S. Verma, S. Merry, A. Lally, B. Kirby and P. Collins
09:50 – 10:00	CD03	<b>Is allergic contact dermatitis of the vulva as common as we think? A tertiary centre experience</b> R. Seys Llewellyn, M. Shah and H. Bell
10:00 – 10:10	CD04	<b>Occupational nitrile glove allergy to Pigment Blue 15</b> C. Reckling, A. Sheraz, M. Engfeldt and M. Bruze
10:10 – 10:20	CD05	<b>Contact dermatitis to a footwear label with positive patch test to 2-monomethylol phenol</b> S. Ziaj, S. Zaheri and S. Wakelin
10:20 – 10:30	CD06	<b>Paraphenylenediamine testing in strongly sensitized patients: an effective screen</b> R. Nalluri, W. Bakkaur and J. Williams
10:30 – 11:15	Break	Exhibition Hall 5
11:15 – 11:35		Guest lecture <b>Methyl isothiazolinone: an update</b> <i>Dr David Orton</i>
11:35 – 11:45	CD07	<b>Methylisothiazolinone and methylchlorisothiazolinone contact allergy: an occupational perspective</b> R. Urwin, K. Warburton, M. Carder, R. Agius and M. Wilkinson
11:45 – 11:55	CD08	<b>Methylisothiazolinone causing glue allergy in a furniture factory</b> C. Wlodek, C.R. Lovell and D.A. Buckley
11:55 – 12:05	CD09	<b>Presumed airborne contact allergy to methylisothiazolinone in paint causing acute severe facial dermatitis and respiratory difficulty</b> W. Alwan, I. White and P. Banerjee
12:05 – 12:15	CD10	<b>Allergic contact dermatitis to Dermabond surgical glue mimicking orthopaedic surgical implant allergy</b> C.P. Harkins, R.M.R. Hearn and S. Abdul Ghaffar
12:15 – 12:25	CD11	<b>What happens to patients after they have been diagnosed with allergic contact dermatitis?</b> J. Simpson, C. Green and S. Abdul Ghaffar
12:25 – 12:35	CD12	<b>A regional audit of cutaneous allergy services</b> V.M. Smith and M. Wilkinson



# BADGEM Clinical Meeting

**Date:** Tuesday 1st July

**Time:** 09:00-13:00

**Room:** Dochart 2

**Chair:** Prof Irene Leigh  
Prof John McGrath



## PROGRAMME

09:00 – 09:05		Welcome BADGEM Clinical Meeting – Professor Irene Leigh
09:05 – 09:30	BG01	Invited Talk 1 <b>What's new in Epidermolysis bullosa?</b> <i>Professor John McGrath (London)</i>
09:30 – 09:40	BG02	Case report 1 <b>Ear complications in inversa type recessive dystrophic epidermolysis bullosa (RDEB-I); a case series of 6 patients</b> Dr Susan Robertson (London)
09:40 – 09:50	BG03	Case report 2 <b>Epidermolysis Bullosa Pruriginosa: Two novel COL7A1 mutations</b> Dr Arpita Debroy Kidambi (Sheffield)
09:50 – 10:15	BG04	Invited Talk 2 <b>Ichthyoses: what's new?</b> <i>Dr Vinzenz Oji (Münster, Germany)</i>
10:15 – 10:25	BG05	Case report 3 <b>Progressive Osseous Heteroplasia</b> Dr Prativa Jayasekera (Liverpool)
10:25 – 10:35	BG06	Case report 4 <b>Acral Peeling Syndrome secondary to CSTA gene mutation</b> Dr Kayria Muttardi (Watford)
10:35 – 10:55	Break	Exhibition Hall 5
10:55 – 11:20	BG07	Invited Talk 3 <b>What's new in keratodermas?</b> <i>Professor Edel O'Toole (London)</i>
11:20 – 11:30	BG08	Case report 5 <b>Vohwinkel syndrome with a novel Loricrin microdeletion</b> Dr Amjad Khan (London)
11:30 – 11:40	BG09	Case report 6 <b>Bullous Ichthyosis of Siemens</b> Dr Anna Dubois (Newcastle)
11:40 – 11:50	BG10	Case report 7 <b>A novel RASA1 mutation presenting with multiple cutaneous capillary malformations</b> Dr Sairan Whitaker (Newcastle)
11:50 – 12:15	BG11	Invited Talk 4 <b>New ways of diagnosing genetic skin disease</b> <i>Professor David Kelsell (London)</i>
12:15 – 12:25	BG12	Case report 8 <b>Focal dermal hypoplasia (Goltz syndrome)</b> Dr Roland Chu (Edinburgh)
12:25 – 12:35	BG13	Case report 9 <b>Annular erythema of infancy? A common disease pathway with atypical HUS</b> Dr Ting Seng Tang (Nottingham)
12:35 – 13:00	BG14	Invited Talk 5 <b>XP and DNA repair. What can a national service offer?</b> <i>Dr Robert Sarkany (London)</i>

Tue 1 July

# British Society for Dermatological Surgery

**Date:** Tuesday 1st July  
**Time:** 11:15-17:30  
**Room:** Alsh  
**Chair:** Dr Raj Mallipeddi & Dr Vindy Ghura  
 Dr Colin Fleming  
 Dr Graeme Stables & Dr Colin Fleming

PROGRAMME		
11:15 – 11:23	DS01	<b>Fluorescence confocal microscopy during Mohs micrographic surgery: will this change everything?</b> E. Craythorne, M. Pavel, R. Mallipeddi, N. Sheth, R. Barlow and A. Bennassar
11:23 – 11:31	DS02	<b>In vivo reflectance confocal microscopy prior to paraffin-fixed 'slow' Mohs micrographic surgery can reduce the number of stages required to clear lentigo maligna</b> M.-L. Daly, N. Anjum, M. Patel, R. Barlow, N. Sheth, R. Mallepedi and E. Craythorne
11:31 – 11:39	DS03	<b>A competency-based assessment tool for Mohs micrographic surgery</b> W. Bakkour and V. Ghura
11:39 – 11:47	DS04	<b>Wrong-site skin surgery in the U.K.: results of a web-based survey</b> S. Rajpara, A. Affleck and C. Fleming
11:47 – 11:55	DS05	<b>Surgical margins identified as a major area of uncertainty in the management of high-risk cutaneous squamous cell carcinoma</b> C. Proby, A. Affleck, L. Thompson, R. Currie, A. Evans, K. Farquhar, G. Gupta, K. Hassan, L. Mackintosh, M. Mathers, C. McLean, C. Moyes, L. Naysmith, J. Norris, T. Shoaib, M. Crumley, W. Ford, F. Oakey, A. Stein and J. Brown
12:00 – 12:30		<b>BCDG Talk 'Management of Surgical Scars'</b> Dr Nick Lowe (London)
12:30 – 12:38	DS06	<b>A case series on the use of topical imiquimod 5% for severe and recurrent keloid scarring</b> Z. Laftah, A. Ujam, N. Baksh, C. Huppa, K. Fan and S. Bashir
12:38 – 12:46	DS07	<b>Clinical and treatment characteristics determining therapeutic outcome in patients undergoing autologous noncultured outer root sheath hair follicle cell suspension for treatment of stable vitiligo</b> K. Vinay, S. Dogra, D. Parsad, A. Kanwar, R. Minz and U. Saikia
12:46 – 12:54	DS08	<b>Combined cell suspension transplantation in stable vitiligo</b> A.P. Holla
12:54 – 13:02	DS09	<b>Modifications of cellular grafting in vitiligo: a new era of surgical management of vitiligo</b> D. Parsad
13:02 – 14:00	Lunch	Exhibition Hall 5
14:00 – 15:00		<b>Focus Session - How to Get out of a Hole</b> Dr Vindy Ghura and Dr Tom Oliphant The session will include: wounds that don't want to close, vessels that won't stop bleeding, invaluable suture tricks and tips, simple flaps and much more
15:00 – 15:40		 <p>Guest Lecture  <b>Dutch Masters: Lessons in Mohs Surgery from the Netherlands</b>  <i>Dr Nicole Kelleners-Smeets (Maastricht, The Netherlands)</i>          Mohs surgery was introduced in the Netherlands in the eighties and our department has experiences with Mohs surgery for more than 25 years. In 1999, our team started the only randomized controlled trial comparing Mohs surgery and conventional excision. We gathered 10 years follow-up data that will be presented. Some report in literature that Mohs surgery can be combined with other treatments like imiquimod or photodynamic therapy. But this combination has disadvantages as well. Despite the meticulous mapping and histological control, recurrences do occur following Mohs. I would like to discuss some of these cases.</p>
15:40 – 16:00	Break	Exhibition Hall 5
16:00 – 16:08	DS10	<b>Lagophthalmos secondary to facial nerve injury in bilobed transposition flap reconstruction of the nasal side wall: a previously unreported complication in dermatological surgery</b> C.B. Hackett, E. Barnes and J.A.A. Langtry

Tue 1 July

16:08 – 16:16	DS11	<b>A 6-month prospective review of all nail presentations to a melanoma screening clinic</b> C.B. Hackett, H. Benbow, T.J. Oliphant and J.A.A. Langtry
16:16 – 16:24	DS12	<b>Paradoxical hair stimulation following laser hair removal: a retrospective study</b> W. Szczecinska, Y. Mansouri, H. McMullin, K. Kitching, S. Lanigan and A. Abdullah
16:24 – 16:32	DS13	<b>Mohs micrographic surgery in the U.K.: are we discriminating against people with blood-borne infections?</b> B.S. McDonald and E.D. Seaton
16:32 – 16:40	DS14	<b>Follicular proliferation or basal cell carcinoma? The first prospective U.K. study of this histological challenge during Mohs surgery</b> N. Anjum, A. Robson, E. Craythorne and R. Mallipeddi
16:40 – 16:48	DS15	<b>What is the best imaging modality for basal cell carcinomas of the external auditory canal and pinna? Aiding Mohs micrographic surgery</b> S. Lokman, C. Perrett and S. Morley
16:48 – 16:56	DS16	<b>Does compression improve wound healing when applied to lower-leg excisions left to heal by secondary intention? The COMPRESS Survey</b> P. Jayasekera, P. Trehan, J. Collins, K.S. Chen, W. Hussain, C. Flohr and E.V. Pynn
16:56 – 17:04	DS17	<b>Mohs micrographic surgery for the treatment of atypical fibroxanthoma: a case series of 16 patients</b> U. Eke, C. Roberts, R. Hejmadi and J. Marsden
17:04 – 17:30		AGM
<b>POSTERS</b>		
	DS18	<b>Castroviejo needle holder: a surgical tip for suturing at difficult anatomical sites</b> A. Patel and S. Varma
	DS19	<b>Merkel cell carcinoma: a U.K. tertiary referral centre 10-year surgical experience</b> I. Logan, M. Petkar, P. Dziewulski and A. Harrison
	DS20	<b>Laser treatment for female facial hirsutism: are quality-of-life benefits sustainable?</b> A. Roche, P. Sedgwick and C. Harland
	DS21	<b>Ingenol mebutate to treat Bowen disease: a case series</b> C. Kiely and C. Buckley
	DS22	<b>The use of an adipomuscular hinge flap for the reconstruction of deep lateral alar defects</b> E. Higgins and R.B.M. Barry
	DS23	<b>Dermal piercings: unregulated high street surgery?</b> G. Parkins and M. Porter
	DS24	<b>Carbon dioxide laser treatments under general anaesthetic: analysis of 124 treatments over 4 years</b> W. Bakkour, V. Madan, S. Dolan and J. Ferguson
	DS25	<b>What is the role of ultrasound evaluation of lymph nodes in patients with high-grade squamous cell carcinoma of the head and neck?</b> S. Mellor, K. Chow and G.B. Colver
	DS26	<b>Histological characteristics of primary cutaneous malignant melanoma excised outside an established pigmented lesion screening clinic</b> S. Verykiou, J.A.A. Langtry and T.J. Oliphant
	DS27	<b>Full-thickness skin grafting is an effective option for the closure of lower limb defects following removal of cutaneous lesions</b> H. Audrain, A. Bray and D. de Berker
	DS28	<b>An audit of Mohs micrographic surgery cases requiring two or more layers that were retrospectively noted to have negative debulk specimens at an Irish tertiary referral centre</b> C.A. Maguire, R.B.M. Barry and P. Ormond
	DS29	<b>The proximal Peng flap: novel use of the Peng flap (pinch modification of advancement and rotation flaps) for proximal nasal dorsum defects in 14 patients</b> C.B. Hackett, T.J. Oliphant, C.M. Lawrence and J.A.A. Langtry
	DS30	<b>Experience in diagnosing melanoma among U.K. dermatology trainees: a nationwide survey</b> C. Champagne, H. Audrain, J. Collins, M. Sommerlad, K. Warburton and B. Esdaile
	DS31	<b>Double-pass pulsed-dye laser therapy at 20-min interval for resistant port-wine stain</b> M.R. Panchal and A. Abdullah
	DS32	<b>Enucleation of cylindromas in Brooke–Spiegler syndrome: a novel surgical technique</b> D. Brass, N. Rajan, T.J. Oliphant and J.A.A. Langtry

DS33	<b>Patient-reported outcome measure of pain experienced during administration of local anaesthesia in cutaneous surgery: a tool for appraisal</b> <u>M.F. Chin, R. Abbott, J.R. Ingram and R.J. Motley</u>
DS34	<b>High-energy laser therapy for the treatment of paradoxical hypertrichosis</b> <u>E. Carras, L. Harris, C. Lavender and C. Harland</u>
DS35	<b>The use of nasalis hinge flap and full-thickness skin graft to recreate contour defect in partial-thickness nasal supratip and tip wounds</b> <u>E. Higgins and R.B.M. Barry</u>
DS36	<b>How should we close scalp wounds? A comparative evaluation of scalp excisions from dermatology and plastic surgery departments at a teaching hospital</b> <u>W. Hunt and E. McGrath</u>
DS37	<b>Overwhelming infection following routine skin surgery: a suggested guideline to prevent surgical-site infection in high-risk cases</b> <u>S. Anthony, K. Batta, F. Tatnall, M. Murdoch, S. Parida and K. Hawks</u>
DS38	<b>Clinical triage tool effective for giving squamoid basal cell carcinoma appropriate treatment priority</b> <u>G. Fremlin, A. Bray and D. de Berker</u>
DS39	<b>An audit on the surgical management of lentigo maligna and melanoma in situ using the 5-mm surgical margin</b> <u>W.Y. Haw, C. Henderson and M. Oakford</u>
DS40	<b>Carbon dioxide laser perforation and extirpation of steatocystoma multiplex</b> <u>W. Bakkour and V. Madan</u>
DS41	<b>Safe surgical management of patients with implantable cardiac devices</b> <u>N. Anjum, N. Child and H. Cooper</u>
DS42	<b>A retrospective study of the quality of histology sections for Mohs micrographic surgery</b> <u>M. Sivaramakrishnan, S. McPherson, A. Evans, S. Rajpara, C. Fleming and A. Affleck</u>
DS43	<b>The effect of blood pressure on bleeding in Mohs surgery</b> <u>A. Kai, C.B. Hackett, T.J. Oliphant, J.A.A. Langtry and C.M. Lawrence</u>
DS44	<b>Treatment of red tattoo ink reaction with carbon dioxide laser and curettage</b> <u>B. Kaur and V. Madan</u>
DS45	<b>Pinch grafting in chronic leg ulceration</b> <u>P. Gazzani, J. Brockley and A. Ilchyshyn</u>
DS46	<b>The usefulness of performing regional scouting biopsies when assessing the clinical significance of a diffuse population of dermal spindle cells when treating lentigo maligna</b> <u>C.A. Maguire, N. Leonard and R.B.M. Barry</u>
DS47	<b>Mohs micrographic surgery referrals in the U.K.: knowledge and perception of Mohs surgeons among general practitioners and physicians in a region in London</b> <u>S. Ziaj and D. Shah</u>
DS48	<b>Median lip fissure of the upper lip: first report of surgical treatment by excision and Z-plasty repair</b> <u>A. Kai, E.L. Speight and J.A.A. Langtry</u>
DS49	<b>Upper lip island pedicle flap repair following Mohs surgery: a case series of 41 patients</b> <u>A. Kai, T.J. Oliphant, C.M. Lawrence and J.A.A. Langtry</u>

The poster viewing session will take place between 13:30 and 14:00 on Tuesday 1st July

## NOTES

---

---

---

---

---

---

---

---

---

---

---







# British Society for Dermatopathology

**Date:** Tuesday 1st July

**Time:** 14:00-17:30

**Room:** Boisdale

**Chair:** Dr Paul Craig & Dr Thomas Brenn  
Dr Eduardo Calonje & Dr Manuraj Singh

Tue 1 July

PROGRAMME		
14:00 – 14:30		AGM
14:30 – 14:35		Introduction and comments on posters
14:35 – 14:44	DP01	<b>Using MITF immunostaining to estimate melanocyte density in lentigo maligna: melanocyte density is greater in recurrent lentigo maligna</b> K. Farquhar and C. Moyes
14:44 – 14:53	DP02	<b>Intravascular epithelioid haemangioma. Review of fifteen cases of a rare malignant mimicker</b> E. Ieremia and E. Calonje
14:53 – 15:02	DP03	<b>Eccrine syringosquamous metaplasia: a mimic of squamous cell carcinoma. Clinicopathological analysis of six cases</b> W. Rickaby, T. Bracey, D. Harmse, U. Brudnick, B. Martin, E. Ieremia and E. Calonje
15:02 – 15:11	DP04	<b>A ten-year retrospective audit of outcomes in patients undergoing sentinel lymph node biopsy for melanoma</b> A. Khan, S.L.P. Chong, J. McGregor, N. Wijesuriya, R. Cerio, C. Harwood and G. Moir
15:11 – 15:20	DP05	<b>The spectrum of dermal hyperneury. Report of six cases</b> E. Ieremia, V. Mudaliar, S. Kelly, B. Grech, P. Rodriguez, B. Martin and E. Calonje
15:20 – 15:29	DP06	<b>Evaluation of follicular T-helper cells in primary cutaneous marginal zone B-cell lymphoma</b> Z. Shukur, D. Greenblatt, M. Ally, F. Child and A. Robson
15:29 – 15:38	DP07	<b>Marginal zone lymphoma, cutaneous lymphoid hyperplasia and atypical marginal zone hyperplasia, unnecessary distinctions and confusion: a proposed solution</b> D. Greenblatt, S. Ziaj, M. Wain, T. Mitchell, S.J. Whittaker, S.L. Morris, F. Child and A. Robson
15:38 – 15:47	DP08	<b>BRAF inhibitor-associated squamoproliferative lesions: evidence of HPV infection histologically but not virologically</b> M. Sommerlad, K. Purdie, H. Rizvi, C. Proby and C.A. Harwood
15:47 – 16:15	Break	Exhibition Hall 5
16:15 – 17:00		Guest lecture <b>What's New in Cutaneous Soft Tissue Tumours?</b> <i>Professor Christopher Fletcher (Boston, USA)</i> This talk will provide a brief overview of selected new topics regarding soft tissue lesions of the skin, including newly recognised 'entities', molecular genetic insights and elements of clinically important differential diagnosis.
17:00 – 17:06	DP09	<b>Epstein-Barr virus associated mucocutaneous ulceration</b> S. Brown, N. Gopee, D. Televantou and C. Lawrence
17:06 – 17:12	DP10	<b>Extensive cutaneous telangiectasia of the torso and limbs: diffuse large B-cell lymphoma with intravascular invasion</b> E. Burden-Teh, D.M. Green, C.G. Millar and K.W. Shum
17:12 – 17:18	DP11	<b>Pigmented follicular squamous cell carcinoma (a subgroup of basosquamous melanocytic tumours)</b> R. Griffiths, N. Turnbull, J.J. Carter, D. Scott, A. Sanders and R.A. Carr
17:18 – 17:24	DP12	<b>An unusual granulomatous variant of scleromyxoedema mimicking diffuse granuloma annulare</b> S. Verykiou, A. Husain and S. Meggitt
POSTERS		
	DP13	<b>Utility of step sections in skin punch biopsies</b> A. Rupani, A. Sa'd and M. Petkar

DP14	<b>Audit of squamous cell carcinoma reporting reveals a high proportion of follicular cases</b> J. Stephenson, R. Griffiths, N. Turnbull, D. Scott, A. Sanders and R.A. Carr
DP15	<b>Clinicopathological features of Merkel cell carcinoma: a 10 year tertiary referral centre experience</b> I. Logan, M. Petkar and D. Kamel
DP16	<b>An immunohistochemical study of myoepithelial cells in cutaneous cystic apocrine neoplasms</b> A. Wood, S.-L. Houghton and A. Biswas
DP17	<b>Clustered scalp cysts: the uncommon naevus trichilemmocysticus</b> J. Collins and P. Hunasehally
DP18	<b>Self healing juvenile cutaneous mucinosis</b> J. M. Gao, J. Mann, K. Abou-Alfa, E. Duarte-Williamson and Eduardo Calonje
DP19	<b>Use of a proforma dramatically improves compliance with RCPATH recommendations for the histopathological reporting of squamous cell carcinoma</b> R. Griffiths, J. Stephenson, N. Turnbull, D. Scott, A. Sanders and R. Carr
DP20	<b>Factor XIIIa identifies macrophages and cells of mesenchymal origin in human skin</b> K. Aljefri, C. Bacon, A. Husain and M. Haniffa
DP21	<b>Twentyfour year retrospective review of the diagnosis and management of lentigo maligna</b> S.H. Hussain, E. Rytina and P. Todd
DP22	<b>Giant condylomata acuminata of Buschke and Lowenstein: a peristomal variant</b> Z.Z.N. Yiu, F.R. Ali and C.C. Lyon
DP23	<b>Septal eosinophilic panniculitis associated with adalimumab therapy for dissecting cellulitis of the scalp</b> P. Pratsou, R. Muc and M.R. Kaur
DP24	<b>Post-irradiation morphea: A report of two cases of an under recognized complication of breast cancer treatment</b> C. Sinclair and A. Biswas
DP25	<b>An unusual rash in the gluteal cleft</b> S. Casey, A. Bakshi, E. Calonje and M. Shah

The poster viewing session will take place between 15:50 and 16:15 on Tuesday 1st July

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

# Plenary Session – submitted papers

**Date:** Tuesday 1st July

**Time:** 14:00-18:00

**Room:** Lomond

**Chair:** Prof Christopher Bunker & Dr Graham Sharpe

Tue 1 July

PROGRAMME		
14:00 – 14:15		Official Opening and Welcome – Professor Christopher Bunker
14:15 – 14:45		<p>Guest Lecture - Introduced by Professor Christopher Bunker</p> <p><b>Vitiligo-an Indian perspective</b></p> <p><i>Professor Amrinder J Kanwar (Greater Noida, India)</i></p> <p>Vitiligo, commonly known as ‘phulwari’ in India is an acquired disorder of pigmentation with a worldwide prevalence of around 0.5-1%. India is amongst the countries with highest prevalence rates ranging from 0.25% to 8.8 %. Loss of cutaneous pigmentation is the result of loss of melanocytes from basal layer of epidermis. Etiopathogenesis of vitiligo is multifactorial and polygenic consisting of genetic, immunological, autoimmune, neurogenic, growth factor defect and environmental factors. The key clinical finding in vitiligo is the acquired onset of an increasing number of depigmented macules, patches and later even wide spread involvement of skin. Patients with vitiligo experience psychosocial distress and social stigmatization due to widespread prejudices, taboos and ignorance among general population. Various treatment options available include medical therapy as well as surgical intervention. I will be covering most of these aspects of vitiligo as seen in Indians.</p>
14:45 – 15:00	O01	<p><b>Population-based mathematical modelling by location analysis and optimisation predicts that investment in phototherapy will widen access and yield financial savings</b></p> <p><u>H. Jones, D. Shipley, L. Smith, V. Knight, P. Harper and A. Anstey</u></p>
15:00 – 15:15	O02	<p><b>Clinically-led referral management: meeting the challenge of increasing dermatology referrals</b></p> <p><u>J. Schofield, C. Armstrong, D. Jackson, K. Scharrer and V. Blankley</u></p>
15:15 – 15:30	O03	<p><b>The psychological burden of common skin diseases in 13 European countries</b></p> <p><u>F. Dalgard, J. Kupfer and U. Gieler</u></p>
15:30 – 16:15	Break	Exhibition Hall 5
16:15 – 16:30	O04	<p><b>Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma</b></p> <p><u>J. Lear, K. Fife, M. Gore, T. Guerrero-Urbano, R. Herd, R. Plummer, N. Basset Seguin, J. Hansson, L. Mitchell, M. Starnawski and A. Hauschild</u></p>
16:30 – 16:45	O05	<p><b>Reflectance confocal microscopy in the management of patients treated with topical 5% imiquimod for facial lentigo maligna</b></p> <p><u>N. Anjum, M. Pavel, A. Coleman, A. Robson, C. Stefanato, R. Mallipeddi, R. Barlow and E. Craythorne</u></p>
16:45 – 17:00	O06	<p><b>Topical diphencyprone immunotherapy as a treatment for cutaneous metastatic malignant melanoma, squamous cell carcinoma and eccrine porocarcinoma: a report of 15 cases</b></p> <p><u>F. Worsnop, A. Kutty, F. Harper, B. Powell and V. Akhras</u></p>
17:00 – 17:15	O07	<p><b>Long-term efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: results from a 52-week randomized, double-blind, placebo-controlled multi-centre trial</b></p> <p><u>S. Dogra, D.S. Krupashankar, P. Naidu and C.G. Prasanna</u></p>
17:15 – 17:30	O08	<p><b>Childhood mycosis fungoides: experience of 28 patients treated in a phototherapy service</b></p> <p><u>P. Laws, E. Pope and N. Shear</u></p>
17:30 – 18:00		<p>Guest Lecture – Introduced by Dr Graham Sharpe</p> <p><b>Behçet’s Syndrome: a new approach</b></p> <p><i>Professor Robert Moots (Liverpool)</i></p>

# Dermatology Teachers

**Date:** Tuesday 1st July

**Time:** 16:30-17:30

**Room:** Dochart 1

**Chair:** Dr Minal Singh

PROGRAMME		
16:30 – 16:45	DT01	<b>Which learning resources do medical students prefer during their dermatology placement?</b> <u>R. Atkar</u> and <u>E. Topham</u>
16:45 – 17:00	DT02	<b>Dermatology teaching for medical students: are we inspiring the next generation?</b> <u>A. Yaakub</u> , <u>C. Wootton</u> and <u>S. Cohen</u>
17:00 – 17:15	DT03	<b>Online dermoscopy: an innovative method for teaching a transferable skill</b> <u>A.A. Atwan</u> , <u>J. Vyas</u> , <u>M. Gonzalez</u> , <u>V. Piguet</u> and <u>R. Gamanya</u>
17:15 – 17:30	DT04	<b>Evaluation of the educational climate for specialty trainees in dermatology</b> <u>J.M.R. Goulding</u> and <u>V. Passi</u>
POSTERS		
	DT05	<b>OpenMed dermatology: selected and rated online resources to support dermatology training and education</b> <u>C. Sinclair</u> , <u>V. Scott-Lang</u> , <u>P. Gordon</u> , <u>N. Turner</u> and <u>A. Sergeant</u>
	DT06	<b>A survey of oral dermatology education and training, knowledge and clinical practice among dermatologists in the U.K. and Ireland</b> <u>K. Heelan</u> , <u>M. Fitzgerald</u> and <u>D. McKenna</u>
	DT07	<b>The case mix and referral patterns of general practitioner graduates of the University College Dublin Diploma in Dermatology</b> <u>I. McDonald</u> , <u>C. Fahy</u> , <u>F. Powell</u> and <u>F. Moloney</u>

*The poster viewing session will take place between 13:30 and 14:00 on Tuesday 1st July*

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

Tue 1 July

# Dermatology: Whose job is it anyway?

A multi-disciplinary debate of the current and future direction of dermatology care

Date: **Wednesday 2 July 2014**

Time: **13.15 – 14.15**

Location: **Dochart**

Meeting chair: **Dr Colin Morton (Stirling)**

## Faculty:

Dr Stephen Keohane (Portsmouth)

Dr George Moncrieff (Bicester)

Mr Taimur Shoaib (Glasgow)

	Discussion topics
13.15 – 13.20	Welcome and introduction
13.20 – 13.35	How can we achieve the optimal patient pathway between primary and secondary care?
13.35 – 13.50	How much dermatology can be effectively managed in the community?
13.50 – 14.05	What should the dermatology service look like in ten years' time?
14.05 – 14.15	Summary and close



# Omalizumab: A new option for addressing unmet clinical needs in Chronic Spontaneous Urticaria (CSU)

Satellite symposium at the  
94th Annual Meeting of  
the British Association of  
Dermatologists

13.15-14.15, WEDNESDAY 2ND JULY 2014  
BOISDALE ROOM, SECC, GLASGOW

Chaired by Dr Clive Grattan, delegates will be provided with iPads to enable interaction with experts in CSU.

- **Navigating the challenges in CSU**  
Dr Clive Grattan and Dr Tabi Leslie
- **Omalizumab in CSU: From trial to clinic**  
Dr Clive Grattan and Dr Alexander Marsland
- **Q&A with symposium faculty**  
Facilitated by Dr Phil Hammond

Lunch will be provided in the room beforehand. Arrive early to guarantee your seat and collect your iPad for the event.



## UK ABBREVIATED PRESCRIBING INFORMATION

### Xolair® (omalizumab) 150mg solution for injection

**Indication:** as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. **Presentation:** Pre-filled syringe of 1ml omalizumab solution (150 mg).

**Dosage and administration:** Xolair treatment should be initiated by physicians experienced in the diagnosis and treatment of chronic spontaneous urticaria. The recommended dose is 300 mg by subcutaneous injection every four weeks. Injections should be administered subcutaneously by a healthcare provider into the deltoid region of the arm, or alternatively, into the thigh. Prescribers are advised to periodically reassess the need for continued therapy. Clinical trial experience of long-term treatment beyond 6 months in chronic spontaneous urticaria is limited.

**Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Precautions:** Not studied in patients with autoimmune diseases, immune complex-mediated conditions, pre-existing renal or hepatic impairment, hyperimmunoglobulin E syndrome, allergic bronchopulmonary aspergillosis or for the prevention of anaphylactic reactions, including those provoked by food allergy, atopic dermatitis, or allergic rhinitis. **Immune system disorders** Type I local or systemic allergic reactions, including anaphylaxis may occur. Most of these reactions occurred within 2 hours after the first and subsequent injections of Xolair, but some started beyond 2 hours and even beyond 24 hours after the injection. Medicinal products for the treatment of anaphylactic reactions should always be available for immediate use following the administration of Xolair. Patients should be informed that such reactions are possible and prompt medical

attention should be sought if allergic reactions occur. Anaphylactic reactions were rare in clinical trials. Antibodies to Xolair have been detected in a low number of patients in clinical trials. Serum sickness and serum-sickness like reactions (delayed type III reactions) have been seen in patients treated with humanized monoclonal antibodies including omalizumab. Onset typically 1-5 days after first or subsequent injections, also after long duration of treatment. Symptoms include arthritis/arthralgias, rash, fever, lymphadenopathy. Antihistamines and corticosteroids may be useful for preventing or treating this disorder. Patients should be advised to report suspected symptoms. **Parasitic (helminth) infections** IgE may be involved in the immunological response to some helminth infections. The helminth infection rate in the overall clinical programme was less than 1 in 1000 patients. Caution may be warranted in patients at high risk of helminth infection. **Drug interactions:** Based on the clearance of Xolair there is little potential for drug-drug interactions. No formal drug interaction studies have been performed. There is no pharmacological reason to expect that commonly prescribed medications used in the treatment of chronic spontaneous urticaria will interact with Xolair. In clinical studies in CSU, Xolair was used in conjunction with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists (LTRAs). There was no evidence that the safety of omalizumab was altered when used with these medicinal products relative to its known safety profile in allergic asthma. In addition, a population pharmacokinetic analysis showed no relevant effect of H2 antihistamines and LTRAs on omalizumab pharmacokinetics. **Undesirable effects:** Common ( $\geq 1/100$  to  $< 1/10$ ): sinusitis, headache, arthralgia, injection site reaction, upper respiratory tract infection. **Arterial thromboembolic**

**events (ATE)** In controlled clinical trials and an observational study, a numerical imbalance of ATE was observed. In a multivariate analysis controlling for baseline cardiovascular risk factors, the hazard ratio was 1.32 (confidence interval 0.91-1.91). In an analysis of pooled clinical trials, which included all randomised double-blind, placebo-controlled clinical trials lasting 8 or more weeks, the rate of ATE per 1,000 patient years was 2.69 (5/1,856 patient years) for Xolair-treated patients and 2.38 (4/1,680 patient years) for placebo patients (rate ratio 1.13, 95% confidence interval 0.24-5.71). **Platelets** No pattern of persistent decrease in platelet counts, as observed in non-human primates has been reported in humans. Isolated cases of idiopathic thrombocytopenia (including serious cases) have been reported in the post-marketing setting. **Parasitic infections** Numerical increase in rate not statistically significant; course, severity and response to treatment unaltered. Prescribers should consult the SmPC for full information regarding other side-effects. **Quantities and basic NHS price (excl. VAT):** 150 mg pre-filled syringe, £256.15. **Marketing authorisation numbers:** EU/1/05/319/008, EU/1/05/319/009 and EU/1/05/319/010. **Legal category:** POM. **Date of last revision of prescribing information:** March 2014. Full prescribing information is available from: Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR. Telephone: (01276) 692255, Fax: (01276) 692508.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis (01276) 698370.

# Wednesday 2 July Overview

WEDNESDAY 2 JULY 2014			
TIME	SESSION DETAIL	ROOM	INFORMATION
08:00 – 08:45	Novartis Sponsored Symposium	Alsh	Page 33
08:00 – 08:45	Celgene Sponsored Symposium	Boisdale	Page 34
08:45 – 10:15	Plenary session – Understanding Pharma	Lomond	Page 35
08:45 – 10:45	Historical	Carron	Page 36
08:45 – 10:15	Commonwealth Session	Dochart	Page 37
08:45 – 10:15	British Teledermatology Society	Leven	Page 38
10:15 – 10:45	Guest Lecturer: Professor Sir Ian Kennedy	Lomond	Page 35
11:15 – 13:00	AGM – BAD members only	Lomond	
11:30 – 12:30	Public Session - Dermatology Question Time	Alsh	Page 39
13:15 – 14:15	Novartis Sponsored Symposium	Boisdale	Page 40
13:15 – 14:15	Roche Sponsored Symposium	Carron	Page 41
13:15 – 14:15	Leo Pharma Sponsored Symposium	Dochart	Page 42
14:30 – 17:50	Plenary session - Medical Dermatology and Submitted Papers	Lomond	Page 43
14:30 – 18:00	British Society for Paediatric Dermatology	Alsh	Page 44-45
15:30 – 18:00	BAD and BDNG Joint Meeting	Boisdale	Page 46
16:15 – 16:45	Hot Topics	Exhibition	Page 58
19:30 – 00:00	Annual Dinner	Kelvingrove Museum	Page 10









# Plenary Session – Understanding Pharma

**Date:** Wednesday 2nd July  
**Time:** 08:45-10:45  
**Room:** Lomond  
**Chair:** Dr Victoria Elegant & Karen Whiteford

Working with Pharma: Regulatory Focus

PROGRAMME		
08:45 – 09:15		<p><b>Bringing the Patient in the centre of our Development</b>            Dr Kim Kjoeller (Senior Vice President Global Development- Leo Pharma)</p> <p>Current success rate for a compound entering first human testing to regulatory approval is 8.5%, in addition only 25-35% of launched products are commercially successful. Reasons for this are:</p> <ul style="list-style-type: none"> <li>• Lack of differentiation</li> <li>• Payers requesting effectiveness data generated from “real life” studies</li> </ul> <p>In order for us to help more patients we therefore need to improve our understanding of unmet patient needs, find ways to document that they are met, and being able to do so in a real life setting. This requires even closer collaborations with thought leaders and patients to direct our future research.</p>
09:15 – 09:45		<p><b>The Development Challenges of Proving Benefit versus Response in Cutaneous T-cell Lymphoma</b>            Dr William McCulloch (President, Alba BioPharm Advisors, Inc.)</p> <p>A physician in clinical practice can usually tell whether any individual patient with visible cutaneous disease has responded to, and derived benefit from, a particular therapeutic intervention. For the pharmaceutical physician and investigators involved in new drug development, however, there is a burden of objective proof that a reasonable proportion of all patients treated in a clinical trial has responded and, furthermore, that the response has led to some accepted clinical benefit, ultimately to be judged by regulatory authorities. This is necessary in order to justify the toxicity and even the cost that will be incurred by treating all patients in a given situation without knowing which specific individuals might benefit from a new therapy (the risk/benefit equation). In CTCL, despite its name, the cutaneous disease is only one component of the overall tumour burden and so the challenge of proving benefit for necessary systemic therapy is more daunting. This will be illustrated by reviewing the recent development of histone deacetylase inhibitors (HDACi) in CTCL.</p>
09:45 – 10:15		<p><b>How regulators can support innovation</b>            Dr Ian Hudson (Chief Executive - Medicines and Healthcare Products Regulatory Agency)</p> <p>Regulators recognise they have a role to enable safe regulation to take place. The MHRA does this in a number of ways including ensuring an appropriate regulatory environment that allows safe innovation to take place, providing guidance, having an innovation office and offering scientific advice. Flexibilities in the regulatory approval processes will be described, and the presentation will include a description of the recently announced Early Access to Medicines Scheme, and European Medicines Agency pilot on adaptive licensing.</p>
10:15– 10:45		<p>Guest Lecture - Introduced by Professor Christopher Bunker  <b>Professional Regulation</b>  <i>Professor Sir Ian Kennedy (London)</i></p>

Wed 2 July

## NOTES

---



---



---



---



---

# Historical Symposium

**Date:** Wednesday 2nd July

**Time:** 08:45 – 10:45

**Room:** Carron

**Chair:** Dr Nick Levell

## PROGRAMME

08:45 – 09:00	H01	<b>Helen Ollendorff-Curth: the first lady of dermatology</b> <i>K.E. Davies and P.D. Yesudian</i>
09:00 – 09:15	H02	<b>Celebrating dendritic cells in the skin: the legacies of Paul Langerhans and Ralph Steinman</b> <i>K. Aljefri and M. Haniffa</i>
09:15 – 09:30	H03	<b>Britain: land of tattooed people</b> <i>S. Unter and A. Shipman</i>
09:30 – 09:45	H04	<b><i>Parthenium</i> dermatitis: the scourge of India</b> <i>J. Jeyatheswaran and P. Yesudian</i>
09:45 – 10:15		Guest Lecture <b>'Eminent Glaswegian Dermatologists'</b> <i>Prof Colin Munro (Glasgow)</i>  Thomas McCall Anderson founded the Glasgow Skin Dispensary in 1861. His Treatise on Diseases of the Skin (1887) includes an analysis of 11,000 consecutive cases. He was the first Professor of Clinical Medicine at the Western Infirmary (opened 1874), and later Regius Professor of Medicine and His Majesty's Physician in Scotland. He was knighted in 1905. Amongst notable subsequent dermatologists are John Ferguson-Smith and Alan Lyell of Glasgow Royal Infirmary, describers of eponymous syndromes, and Herbert Brown of the Victoria Infirmary, with his striking collection of dermatological photographs.
10:15 – 10:45	Break	<b>Historical Tea</b> Please join us for Madeira cake and wine in memory of Robert Willan

## POSTERS

	H05	<b>Alan Lyell (1917–2007) and his eponymous disease</b> <i>A. Hamilton</i>
	H06	<b>From ancient Indian potters to WWII pilots: the elaborate history of skin grafting</b> <i>R. Jerrom, D. Jackson, A. Patel and S. Varma</i>
	H07	<b>Dr Albert Sézary (1880–1956) and his monster cells</b> <i>D. Tabor and V. Smith</i>
	H08	<b>The rise and fall of topical corticosteroids in dermatology</b> <i>R. Coelho and N.J. Levell</i>
	H09	<b>History of retinoids: from blindness to beauty</b> <i>N. Spierings and J. Natkunarajah</i>
	H10	<b>Man and melanoma: a long battle through time</b> <i>P. Mahendran and J. Natkunarajah</i>
	H11	<b>Campbell Grieg de Morgan (1811–76): not just a spot diagnosis</b> <i>D. Tabor and V. Smith</i>
	H12	<b>Is Shakespeare to blame for the negative connotations of skin disease?</b> <i>C. Wootton, N. Boyle and T. Bleiker</i>
	H13	<b>Ferdinand-Jean Darier: a vivacious man</b> <i>J. Collins, N. Ponnambath and M. Kalavala</i>
	H14	<b>The end of an era: Donald L. Morton (1934–2014) – the pioneer of sentinel lymph node biopsy</b> <i>A.R. Shipman and B.C. Gee</i>
	H15	<b>The history of local anaesthetic</b> <i>A. Patel and S. Varma</i>
	H16	<b>History of the use of radiation in dermatology</b> <i>V.C.Y. Li and R.K. Lister</i>
	H17	<b>From ancient civilization to the 21st century: acne treatment through the ages</b> <i>K. Bhate and R. Simpson</i>

The poster viewing session will take place between 16:00 and 16:45 on Wednesday 2nd July



# Commonwealth Session

**Date:** Wednesday 2nd July

**Time:** 08:45 – 10:15

**Room:** Dochart

**Chair:** Prof Vinod Sharma & Prof Amrinder J Kanwar

## PROGRAMME

08:45 – 08:55	CS01	<b>Childhood leprosy through post- leprosy elimination era : a retrospective analysis of epidemiological and clinical characteristics of disease over eleven years from a tertiary care hospital at North India</b> S. Dogra, T. Narang, G. Khullar, R. Kumar and Uma Saikia
08:55 – 09:05	CS02	<b>The active edge, centre or adjacent normal skin have the better histological yield in the diagnosis of tuberculoid leprosy</b> F. Srisaravanapavananthan, K. Satgurunathan and J. Fernando
09:05 – 09:15	CS03	<b>A prospective case series evaluating efficacy and safety of itraconazole and potassium iodide in rhinofacial conidiobolomycosis</b> T. Narang, M. Gupta, R. Kaur and A. Manhas
09:15 – 09:25	CS04	<b>Amyloidosis cutis dyschromica in two siblings and review of the epidemiology, clinical features and management</b> C. Mahon, F. Oliver, D. Purvis and K. Agnew
09:25 – 09:35	CS05	<b>Fibroscan Monitoring for Liver Complications of Methotrexate Use in Dermatology Patients</b> A. Chandran, M. Rademaker, R. Vyas, A. Yung, E. Johns, R. Jurawan, J. Irwin and F. Weilert
09:35 – 09:45	CS06	<b>A prospective study of childhood leprosy from 2001 to 2014</b> J. Seneviratne, J. Akarawita, N. Madarasinghe and C. Siriwardana
09:45 – 09:55	CS07	<b>Leprosy controversies: in therapy and its elimination</b> B. Kumar
09:55 – 10:05	CS08	<b>A randomized comparative study between autologous noncultured epidermal cell suspension, suction blister epidermal grafting and split-thickness skin grafting: a quest to find a first-line surgical modality for the treatment of stable vitiligo</b> A. Budania, D. Parsad, S. Dogra and N. Khunger
10:05 – 10:15	CS09	<b>Herpes zoster in Sri Lanka</b> D. Bandara, M.T. Wickramasinghe, R. Weerasekara, D. Dissanayake and W. Ranaraja

## POSTERS

	CS10	<b>The challenge of managing pityriasis rubra pilaris: success at last with ustekinumab?</b> S.H. Foo, A. Rowe, M.B. Maheshwari and A. Abdullah
	CS11	<b>Psoriasis audit: secondary care vs. intermediate care for the assessment and management of psoriasis</b> R. Atkar and E. Derrick
	CS12	<b>Pemphigus and associated comorbidities: a Canadian population-based study</b> K. Heelan, A. Maher, S. Walsh and N.H. Shear
	CS13	<b>Invasive granulomatous aspergillosis mimicking cervicofacial actinomycosis in an immunocompetent host</b> S. Kumaran and S. Dogra
	CS14	<b>Skin disease and infective endocarditis: a review of cases in New Zealand children, 994–03</b> C. Mahon, H. Cheng, R. Webb, D. Purvis and K. Agnew
	CS15	<b>An uncommon fungal infection of the skin associated with granulocytic sarcoma: a diagnostic dilemma</b> K. Mallawaarachchi, S. Mendis, S. Ratnayake
	CS16	<b>Autologous serum skin test vs. autologous plasma skin test in patients with chronic spontaneous urticaria: is there a response correlation?</b> S. Kumaran, S. Manal and D. Parsad
	CS17	<b>Deep vein thrombosis following thalidomide therapy in a patient with erythema nodosum leprosum receiving multibacillary multidrug therapy and prednisolone</b> A. Budania and H.K. Kar
	CS18	<b>Clinical and investigational profile of herpes genitalis in a tertiary care centre</b> A. Itty, B. Joy and R. Sridharan
	CS19	<b>A survey of dermatological conditions in northern India: are we seeing changes reflecting urbanization?</b> F. Latheef and Roland Strauss
	CS20	<b>Moxifloxacin-based regimens in leprosy: interim observations on occurrence of reactions and bacterial decline</b> V.V. Pai

The poster viewing session will take place between 10:45 and 11:15 on Wednesday 2nd July





# The British Association of Dermatologists invite the public to a Dermatology Question Time.



The session, hosted by Journalist, Broadcaster and former BBC & ITN newscaster Martyn Lewis will be held on 2<sup>nd</sup> July from 11.30 to 12.30 in the Alsh Room at the SECC, Glasgow as part of the British Association of Dermatologists Annual Meeting.

Members of the public can ask questions of a distinguished panel of experts and join in the debate on wide-range of skin-health related issues.

**The event is free . Please visit the on-site registration desk for a ticket**

- Around 13 million people a year visit their GP in relation to a skin condition.
- Skin cancer is the most numerous cancer in the UK and is increasing in incidence.
- Hand eczema is one of the most common reasons for disablement benefit in the UK

## Who should attend?

Anyone interested in skin-health or skin-conditions  
Representatives from local patient support groups  
Students with an interest in health  
Occupational health workers  
Union representatives  
Employers  
Health workers

## The Panel – Chaired by broadcaster Martyn Lewis OBE

Dr David Orton

Consultant Dermatologist

Dr Orton is President of the British Society of Cutaneous Allergy. He has recently been involved in alerting the public and regulatory authorities to the dangers of MI (methylisothiazolinone). Dr Orton specialises in: Skin Allergy (diagnostic patch testing), and General Allergy to airborne allergens (pollens, dust mites, animal danders) food allergies/intolerances, drug allergies, latex allergy (skin prick tests and intradermal tests) and the management of urticaria and angioedema.

Dr Tamara Griffiths

Consultant Dermatologist

Dr Griffiths is an expert in anti-ageing and cosmetic procedures. She has been at the forefront of the BAD's input into the Keogh Review into the regulation of non-invasive cosmetic procedures. She is currently a Consultant Dermatologist at the Dermatology Centre, Salford Royal NHS Trust, she has expertise in the diagnosis and management of diseases of the skin, hair and nails.

Professor Lesley Rhodes

Professor of Experimental Dermatology

Professor Rhodes is an expert in the effects of UV radiation on skin. She has published research on this subject and is currently the topic expert on the NICE consultation of the Risks and Benefits of Sunlight. She runs a supra-regional diagnostic service in photosensitivity disorders and photodynamic therapy for skin cancer treatment. Her research programme focuses on the mechanisms of visible and ultraviolet radiation effects on the skin, including inflammation, vitamin D synthesis, photodynamic therapy, photosensitivity disorders and the development of photoprotection including dietary and hormonal measures. She has over 150 publications with the majority as first or last author.

Dr Daniel Kemmett

Consultant Dermatologist

Dr Kemmett is President Elect of the Scottish Dermatological Council. He is currently a Consultant Dermatologist at the Western Infirmary, Glasgow. His training and practise covers all aspects of dermatology, his main interests are skin cancer and surgery as well as the clinical and genetic aspects of psoriasis. He is also interested in medical education especially the teaching of post graduates on various aspects of dermatology.

[www.bad.org.uk](http://www.bad.org.uk) | 020 7383 0266 | Charity reg no. 259474 | Willan House, 4 Fitzroy Square, London W1T 5HQ | @healthyskin4all

Wed 2 July



# Sponsored Symposium: Novartis Pharmaceuticals UK Ltd

Date: Wednesday 2nd July

Time: 13:15-14:15

Room: Boisdale

Chair: Dr Clive Grattan



Omalizumab: A new option for addressing unmet clinical needs in Chronic Spontaneous Urticaria (CSU)

PROGRAMME	
13:15 – 13:18	<b>Welcome &amp; Introduction</b> Dr Phil Hammond (London)  Navigating the challenges in CSU
13:18 – 13:25	<b>Confirming diagnosis and assessing impact on quality of life</b> Dr Clive Grattan (Norwich)
13:25 – 13:35	<b>Limitations of current treatment options and guidelines</b> Dr Tabi Leslie (London)  Omalizumab in CSU: From trial to clinic
13:35 – 13:50	<b>Phase III data: Efficacy and safety in CSU</b> Dr Clive Grattan (Norwich)
13:50 – 14:00	<b>Real-world patient outcomes</b> Dr Alexander Marsland (Manchester)  Panel discussion and summary
14:00 – 14:12	<b>Q &amp; A with symposium faculty</b> Facilitated by Dr Phil Hammond (London)
14:12 – 14:15	<b>Closing Remarks</b> Dr Clive Grattan (Norwich)

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

Wed 2 July



# Sponsored Symposium: Roche Products Ltd

**Date:** Wednesday 2nd July  
**Time:** 13:15-14:15  
**Room:** Carron  
**Chair:** Dr John Lear



Erivedge® ▼ (vismodegib) in advanced Basal Cell Carcinoma patients inappropriate for surgery or radiotherapy – A UK case study based approach

PROGRAMME	
13:15	<b>Welcome &amp; Introductions</b> Dr John Lear, Consultant Dermatologist – Central Manchester University Hospital
13:20	<b>Targeting the Hedgehog pathway in advanced Basal Cell Carcinoma (BCC) inappropriate for surgery or radiotherapy</b> Dr John Lear, Consultant Dermatologist – Central Manchester University Hospital
13:40	<b>UK Patient Case Studies – an MDT based approach</b> Dr Kate Fife, Consultant Clinical Oncologist & Mr Amer Durrani, Consultant Plastic Surgeon – Addenbrooke's, Cambridge University Hospital NHS Foundation Trust
14:05	<b>Closing Remarks</b> Dr John Lear (Manchester)
14:15	<b>Close</b>

This promotional symposium has been organised by Roche Products Limited  
 RXUKERIV00092a(1) June 2014

## Prescribing Information

**ERIVEDGE® (vismodegib)** 150 mg hard capsules

**Indication:** Erivedge is indicated for the treatment of adult patients with:

- symptomatic metastatic basal cell carcinoma (mBCC)
- locally advanced basal cell carcinoma (laBCC) inappropriate for surgery or radiotherapy.

**Dosage and administration:** Recommended daily dose is 150 mg taken orally with or without food. Swallow capsules whole with water. If a dose is missed resume with the next scheduled dose. Treatment interruptions of up to 4 weeks were allowed based on individual tolerability. In clinical trials, treatment with Erivedge was continued until disease progression or until unacceptable toxicity.

**Contraindications:** Women who are pregnant, breast feeding or women of childbearing potential (WCBP) who do not comply with the Erivedge Pregnancy Prevention Programme. Hypersensitivity to the active substance or excipients. Coadministration of St John's wort (*Hypericum perforatum*)

**Precautions and Warnings:** *Embryo-foetal death or severe birth defects:* Due to the risk of embryo-foetal death or severe birth defects women taking Erivedge must not be pregnant or become pregnant during treatment and for 24 months after the final dose. If the patient does become pregnant, misses a menstrual period, or suspects for any reason that she may be pregnant, she must notify her treating physician immediately. *Counselling:* WCBP and men who are prescribed Erivedge must comply with the Erivedge Pregnancy Prevention Programme. WCBP must use two methods of recommended contraception, including one highly effective method and a barrier method during Erivedge therapy and for 24 months after the final dose. *For men:* Erivedge is contained in semen. Male patients should not donate semen while taking Erivedge and for 2 months after the final dose. To avoid potential foetal exposure during pregnancy, male patients must always use a condom (with spermicide, if available), even after a vasectomy, when having sex with a female partner while taking Erivedge and for 2 months after the final dose. *Blood donation:* Patients should not donate blood while taking Erivedge and for 24 months after the final dose. *Cutaneous squamous cell carcinoma (cuSCC):* Patients with advanced BCC have an increased risk of developing cuSCC. All patients should be monitored routinely while taking Erivedge, and cuSCC should be treated according to the standard of care. *Excipients:* Erivedge contains lactose monohydrate, therefore patients with galactose intolerance, primary hypolactasia or glucose-galactose malabsorption should not take this medicinal product. *Interactions:* Concomitant treatment with strong CYP inducers (e.g. rifampicin, carbamazepine or phenytoin) should be avoided, as a risk for decreased plasma concentrations and decreased efficacy of vismodegib cannot be excluded.

**Drug Interactions:** Drugs that alter the pH of the upper gastrointestinal (GI) tract (e.g.,

proton pump inhibitors H<sub>2</sub>-receptor antagonists, and antacids) may alter the solubility of Erivedge and reduce its bioavailability. *In vitro* studies indicate that vismodegib is a substrate of the efflux transporter P-glycoprotein (P-gp) and the drug metabolising enzymes CYP2C9 and CYP3A4. When vismodegib is co-administered with medicinal products that inhibit P-gp (e.g. clarithromycin, erythromycin, azithromycin, verapamil, cyclosporin), CYP2C9 (amiodarone, fluconazole, miconazole), or CYP3A4 (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazole), systemic exposure of vismodegib and incidence of adverse events of vismodegib may be increased. Results of a drug-drug interaction study conducted in cancer patients demonstrated that the systemic exposure of ethinyl estradiol and norethindrone is not altered when co-administered with vismodegib. However, the interaction study was of only 7 days duration and it cannot be excluded that vismodegib upon longer treatment is an inducer of enzymes which metabolise contraceptive steroids. Induction could lead to decreases in systemic exposure of the contraceptive steroids and thereby reduced contraceptive efficacy.

**Fertility/pregnancy/lactation:** See precautions and warnings with regards to pregnancy. In case of pregnancy in a woman treated with Erivedge, treatment must be stopped immediately. The extent to which Erivedge is excreted in breast milk is not known. Due to its potential to cause serious developmental defects women must not breast-feed while taking Erivedge and for 24 months after the final dose. Amenorrhoea has been observed in clinical trials in WCBP. Fertility preservation strategies should be discussed with WCBP prior to starting treatment with Erivedge.

**Adverse reactions:** See SmPC for full details. In general the safety profile observed was consistent in both mBCC and laBCC patients. *Very common:* muscle spasms, alopecia, pruritus, dysgeusia, weight decrease, fatigue, decreased appetite, nausea, amenorrhoea, ageusia, diarrhoea, constipation and vomiting. *Common:* dehydration, hyponatremia, hypogeusia, dyspepsia, upper abdominal pain, abdominal pain, rash, madarosis, abnormal hair growth, arthralgia, pain in extremity, back pain, musculoskeletal chest pain, myalgia, flank pain, musculoskeletal pain, pain, asthenia and hepatic enzymes increased.

**Legal category:** POM. **Presentation:** 28 hard capsules (bottle) **Basic NHS Costs:** £6,285. **Marketing authorisation number:** EU/1/13/848/001 The conditional marketing authorisation means submission of additional data from ongoing studies is required to maintain approval for use. **Marketing authorisation holder:** Roche Registration Ltd, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom. Erivedge is a registered trade mark. RXUKMEDI00145 **Date of preparation:** July 2013

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing [welwyn.uk\\_dsc@roche.com](mailto:welwyn.uk_dsc@roche.com) or calling +44(0)1707 367554.

Wed 2 July



# Sponsored Symposium: LEO Pharma

**Date:** Wednesday 2nd July  
**Time:** 13:15-14:15  
**Room:** Dochart  
**Chair:** Dr Colin Morton



**Dermatology: Whose job is it anyway? A multi-disciplinary debate of the current and future direction of dermatology care**

PROGRAMME	
13:15 – 14:15	Faculty: Mr Taimur Shoaib (Glasgow) Dr George Moncrieff (Bicester) Dr Stephen Keohane (Portsmouth) Discussion topics: How can we achieve the optimal patient pathway between primary and secondary care? How much dermatology can be effectively managed in the community? What should the dermatology service look like in ten years’ time? Summary and close

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

Wed 2 July

# Plenary Session – Medical Dermatology & Submitted Papers

**Date:** Wednesday 2nd July  
**Time:** 14:30 – 17:50  
**Room:** Lomond  
**Chair:** Dr Sarah Walsh & Dr Nick Levell  
 Dr Tabi Leslie & Dr Mike Ardern-Jones

PROGRAMME		
14:30 – 14:55	MD01	<b>Psychological aspects of psoriasis</b> <i>Dr Sandy McBride (London)</i>
14:55 – 15:10	O09	<b>Do the brains of psoriasis patients exhibit neuroinflammation?</b> <u>H.J.A. Hunter</u> , R. Hinz, X. Su, P.P.S. Talbot, A. Gerhard, C.E.M. Griffiths and C.E. Kley
15:10 – 15:25	O10	<b>Oral ciclosporin compared against prednisolone in pyoderma gangrenosum: a randomized controlled trial</b> A. Ormerod, J. Norrie, E. Harrison, E. Mitchell, K. Thomas, H. Williams, Stop Gap Trial Group Collaborators, N. Greenlaw, J. Mason, and F. Craig
15:25 – 15:50	MD02	<b>Atopic eczema: new concepts in pathogenesis and treatment</b> <i>Dr Mike Ardern-Jones (Southampton)</i>
15:50 – 16:05	O11	<b>Shared decision-making in plaque psoriasis: development of an Option Grid to assist in decisions to commence oral therapy</b> <u>E. Farrell</u> , R. Whistance, A. Lloyd, M.-A. Durand, A. Jones, G. Elwyn and R. Motley
16:05 – 16:45	Break	Exhibition Hall 5
16:45 – 17:10	MD03	<b>Ehlers Danlos and PXE</b> <i>Dr Nigel Burrows (Cambridge)</i>
17:10 – 17:25	O12	<b>A 10-year review of patients with vulval vestibulitis syndrome referred into a multidisciplinary clinic</b> <u>E.E. Merika</u> , C. Borysiewicz, S. Zaheri, J. Carton, A. Toczek, D. Lyons, M. Byrne and J. Setterfield
17:25 – 17:50	MD04	<b>Skin problems of HIV post HAART</b> <i>Dr David Paige (London)</i>

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

Wed 2 July

# British Society for Paediatric Dermatology

**Date:** Wednesday 2nd July  
**Time:** 14:30 – 18:00  
**Room:** Alsh  
**Chair:** Dr Mary Glover & Dr Ruth Murphy

## PROGRAMME

14:30 – 14:40	PA01	<b>The genetic basis of phakomatosis pigmentovascularis type II</b> R. Waelchli, A. Thomas and V. Kinsler
14:40 – 14:50	PA02	<b>Assessing the reliability of exome sequencing to detect the filaggrin null mutations R501X and 2282del4</b> B. Thompson, D. Hawcutt, D. Carr, K. Bloch, A. Swale, R. Smyth and M. Pirmohamed
14:50 – 15:00	PA03	<b>Propranolol In the Treatment of Complicated Haemangiomas (PITCH): the European perspective</b> E. Wedgeworth, E. Baselga, J. Bjerre, M. Deleuran, V. Dorkova, R. Foelster-Holst, M. Glover, L. Hedelund, A. Hernandez-Martin, P. Hoeger, A. Irvine, I. Neri, A. Oranje, A. Patrizi, J. Ravenscroft, H. Shahidullah, L. Solman Koustic, A. Svensson, C.-F. Wahlgren and C. Flohr
15:00 – 15:10	PA04	<b>Facial port wine stain and glaucoma: an audit in two tertiary laser units</b> R. Raghavendran, A. Abdullah and M. Ogboli
15:10 – 15:20	PA05	<b>Propranolol-related hypoglycaemic seizure in a 9-month-old infant: the importance of regular feeding throughout the course of treatment</b> D. Owen and J. Hughes
15:20 – 15:30	PA06	<b>Naevus spilus congenital melanocytic naevi: a distinct genotype for a distinct phenotype</b> V. Kinsler, S. Krenzel and R. Waelchli
15:30 – 16:15		Guest Lecture <b>Ehlers Danlos Syndrome in Childhood</b> <i>Dr Glenda Sobey (Sheffield)</i> The term Ehlers Danlos Syndrome refers to a heterogeneous group of inherited connective tissue disorders. These can present in childhood to dermatologists with a variety of skin manifestations. Some forms of EDS are life threatening and it is important that these are recognised early and managed appropriately. The various presentations of EDS in childhood will be discussed together with the role of molecular genetic testing. The EDS National Diagnostic Service accepts referrals from consultants in secondary care for the diagnosis of complex forms of EDS.
16:15 – 16:45	Break	Exhibition Hall 5
16:45 – 16:53	PA07	<b>Peeling the surface of cystatin A defects</b> K. Muttardi, D. Nitoiu, D.P. Kellsell, E.A. O'Toole and K. Batta
16:53 – 17:01	PA08	<b>Enterovirus infection mimicking eczema herpeticum: a new entity?</b> V. Scott-Lang, C. Sinclair, J. Yoo, N. Nwafor, H. Harvala, B. Dylan and S. Olivia
17:01 – 17:09	PA09	<b>Ichthyosis with striate keratoderma caused by a compound heterozygous mutation in ichthyin/NIPAL4</b> M. Sommerlad, C. Scott, C. Harwood, D. Kellsell and E. O'Toole
17:09 – 17:17	PA10	<b>The effectiveness of a written treatment plan in the management of children with atopic eczema</b> C. Duhovic, M. Mohsin, E. Duarte-Williamson and S. Baron
17:17 – 17:25	PA11	<b>Disease severity measures and quality of life in atopic eczema in children</b> Z.K. Jabbar-Lopez, S. Darne, A.E.M. Taylor and N.J. Reynolds

Wed 2 July

17:25 – 18:00



Guest Lecture  
**Paediatric Dermatology at the Regional Dermatology Training Centre, Moshi, Tanzania**  
*Dr Susannah Baron (Canterbury)*

Susannah Baron took a 6 month sabbatical between November 2011 and May 2012. She travelled to Moshi, Tanzania with her husband and two sons aged 6 and 7 to teach at the RDTTC in Moshi. The RDTTC provides local dermatological care and training for Registrars, medical officers and medical students from sub-Saharan Africa. Susannah concentrated on providing Paediatric dermatology training based around the clinical cases managed each week. This presentation will discuss cases including connective tissue and blistering disease, tropical infections, vascular lesions, HIV related skin disease and genodermatoses. Susannah will also share the delights of living and working in Tanzania.

**POSTERS**

PA12	<b>An interesting case of keratin-1-mutation epidermolytic epidermal naevus and unilateral distal limb aplasia</b> <i>Y. Oon, C. Charman, E. Kivuva and D. Bartle</i>
PA13	<b>Multifocal lymphoendotheliomatosis with thrombocytopenia</b> <i>K. Aljefri, F. Charlton, S. Leech and A.E.M. Taylor</i>
PA14	<b>The perineal groove: an uncommon congenital anomaly of the perineum</b> <i>E. Higgins, F. Quinn and R. Watson</i>
PA15	<b>Spontaneously regressing eruptive disseminated Spitz naevi</b> <i>B. Bhojru, D. Tang, C. Harikumar and A. Carmichael</i>
PA16	<b>An interesting presentation of papular xanthomas in a 5-year-old girl</b> <i>R. Seys Llewellyn, A. Alsharqi and R. Parslew</i>
PA17	<b>Coxsackievirus A6 preferentially affecting children with atopic dermatitis in the U.K.</b> <i>M. Lynch, A. Sears, H. Cookson, T. Lew, Z. Laftah, E. Orrin, M. Zuckerman, D. Creamer and E. Higgins</i>
PA18	<b>Lamellar ichthyosis with a novel mutation in the ABCA12 gene</b> <i>F. Latheef, M. Shareef and B. Walker</i>
PA19	<b>Neonatal lupus erythematosus with life-threatening gastrointestinal bleeding</b> <i>V. Dvorakova, B. Nolan, A. Broderick, E.J. MacDermott and R. Watson</i>
PA20	<b>Influenza vaccination as a novel trigger of Wells syndrome in a child</b> <i>J. Simpson, R. Patalay, N. Roberts and Nick Francis</i>
PA21	<b>Successful treatment of chronic bullous disease of childhood with rituximab</b> <i>N. Farquharson, R. Wynn and T. Clayton</i>
PA22	<b>Invasive fungal dermatitis of the very low birthweight infant</b> <i>A. Fonia, C. Kennedy, P. Mannix and C. Platt</i>
PA23	<b>A case of blueberry muffin baby associated with a blastic plasmacytoid dendritic cell neoplasm</b> <i>A. Lloyd-Lavery, J. Aspel, S. Wilson, K. Lakhoo, E. Soilleux and T. McPherson</i>
PA24	<b>Bathing suit ichthyosis and 22q11.2 duplication</b> <i>A. Khan and A. Harrison</i>
PA25	<b>Bullous erythrodermic rash in a neonate: diffuse cutaneous mastocytosis</b> <i>R. Davies, R. El-Sharkawi and S. Blackford</i>
PA26	<b>Pachydermodactyly: an unusual case of swollen fingers managed successfully with surgery</b> <i>F. Latheef and D. Fairhurst</i>
PA27	<b>Familial myofibromatosis associated with germline CDKN2A mutations</b> <i>K. Aljefri, A. Dubois, A. Husain, A. Henderson, N. Rajan and S. Leech</i>
PA28	<b>Imiquimod cream for treatment of a child with Gorlin syndrome</b> <i>Y. Robson and R. Goodwin</i>
PA29	<b>Hypopigmented mycosis fungoides in a 4-year-old Zimbabwean boy</b> <i>V.M. Smith and S. Clark</i>
PA30	<b>Hypothyroidism and hepatic haemangiomas: highlighting the link</b> <i>C. Wootton and J. Ravenscroft</i>
PA31	<b>A boy and his guinea pig: the importance of taking a pet history</b> <i>S. Ayob, N. Aldoori and M. Cork</i>
PA32	<b>X-linked ichthyosis: a rare mutation and dramatic improvement with topical therapy</b> <i>B. McDonald and B. De Silva</i>
PA33	<b>Recurrent eczema herpeticum secondary to herpes simplex virus type 2: a case study and review of the literature</b> <i>F. Meredith and F. Muller</i>
PA34	<b>Microsporium audouinii infection complicating atopic dermatitis in a 5-year-old girl</b> <i>P. Gazzani, W. Szczecinska and A. Ilchyshyn</i>

Wed 2 July

The poster viewing session will take place between 16:15 and 16:45 on Wednesday 2nd July



# Thursday 3 July Overview

## THURSDAY 3 JULY 2014

TIME	SESSION DETAIL	ROOM	INFORMATION
07:30 – 08:30	Christian Medical Fellowship Breakfast	Ness	
08:45 – 12:40	Plenary Session Professors & Registrars forum	Lomond	Page 48
08:45 – 12:45	British Photodermatology Group	Alsh	Page 49-50
08:50 – 12:30	British Society for Skin Care in Immunocompromised Individuals	Carron	Page 52-53
13:30 – 14:15	Arthur Rook Oration: Dr Rachael Clark	Lomond	Page 54
14:15 – 17:00	CPD update	Lomond	Page 54
15:00 – 15:30	Focus Session - Alopecia	Alsh	Page 55
15:00 – 15:30	Focus Session - Itch	Boisdale	Page 55
15:00 – 15:30	Focus Session - Hyperhidrosis	Carron	Page 55
15:30 – 16:00	Guest Lecturer: Professor Vinod Sharma	Lomond	Page 54

# Professors & Registrars Forum

**Date:** Thursday 3rd July  
**Time:** 08:45 – 12:40  
**Room:** Lomond  
**Chair:** Dr David Eedy & Prof Irene Leigh  
 Dr Richard Groves & Prof Eugene Healy

PROGRAMME		
08:45 – 09:00	PRES	<b>Presidents Address</b> <i>Dr David Eedy</i>
09:00 – 09:15	RF01	<b>Severity of polymorphic light eruption in pre- and postmenopausal women: a comparative study</b> <i>H. Reddy, S. Wahie and A.J. Carmichael</i>
09:15 – 09:30	RF02	<b>Yellow nail syndrome: a primary lymphatic disorder?</b> <i>Z. Jiyad, E. Cousins, A. Stanton and P. Mortimer</i>
09:30 – 09:50	PR01	<b>Disordered immune homeostasis, autoimmunity and implications for dermatological therapies</b> <i>Prof Anthony Ormerod (Aberdeen)</i>
09:50 – 10:05	RF03	<b>Novel mutation in loricrin presenting with prominent ichthyosis</b> <i>F. Cunningham, E. Pohler, A. Sandilands, C. Cole, F. Smith, I. McLean, C. Munro and M. Zamiri</i>
10:05 – 10:20	RF04	<b>Meeting the NICE guideline: a simple, targeted ultrasound protocol for the detection of early psoriatic arthritis in patients with severe psoriasis</b> <i>L. Savage, A. Jackson, M. Goodfield and D. McGonagle</i>
10:20 – 10:40	PR02	<b>Pustular phenotypes of psoriasis</b> <i>Prof David Burden (Glasgow)</i>
10:40 – 11:10	Break	Exhibition Hall 5
11:10 – 11:25	RF05	<b>Self-generated lysophosphatidic acid gradients are a key driver of melanoma cell dispersal &amp; invasion</b> <i>A. Muinonen-Martin, W. Faller, O. Susanto, O. Sansom, L. Machesky, R. Insall, M. Wakelam, Q. Zhang, R. Herd, R. Jones, D. Bennet and D. Knecht</i>
11:25 – 11:40	RF06	<b>Skin-related mortality after kidney transplantation in England between 2001 and 2012: a population-based cohort analysis</b> <i>H. Church, D. Farrugia, I. Begaj, D. Ray and A. Sharif</i>
11:40 – 12:00	PR03	<b>Personalising systemic therapy in psoriasis</b> <i>Prof Catherine Smith (London)</i>
12:00 – 12:15	RF07	<b>Determinants of Varicella Zoster Virus replication in skin</b> <i>M. Singh</i>
12:15 – 12:30	RF08	<b>Induction of dermal papilla properties in highly potent CD271+CD90+ mesenchymal stem cells generated from human-induced pluripotent stem cells</b> <i>O. Veraitch, Y. Mabuchi, Y. Matsuzaki, M. Amagai, H. Okano and M. Ohyama</i>
12:30 – 12:40	PR04	<b>Update on BADBIR</b> <i>Prof Chris Griffiths (Manchester)</i>

## NOTES

---



---



---



---



---



---



---



---



---



---



---



---



---



---



---

Thur 3 July





# British Photodermatology Group

**Date:** Thursday 3rd July

**Time:** 08:45 – 12:45

**Room:** Alsh

**Chair:** Prof James Ferguson & Dr Robert Sarkany  
Dr Victoria Goulden & Dr Robert Dawe

PROGRAMME		
08:45 – 09:00	PD01	<b>British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen combined with ultraviolet A therapy 2014</b> <u>T.C. Ling</u> , T.H. Clayton, J. Crawley, L.S. Exton, V. Goulden, S. Ibbotson, K. McKenna, M.F.M. Mustapa, L.E. Rhodes, R. Sarkany and R.S. Dawe
09:00 – 09:35		Guest Lecture <b>Measuring sun behaviour in normals and patients</b> <i>Prof Hans Christian Wulf (Copenhagen)</i> Sun behaviour is highly influenced by occupation, outdoor sports, sun vacations, and solarium use. We have used electronic dosimeters to measure UV exposure continuously throughout several seasons. Danish indoor workers get a yearly UV dose of about 130 SED, whereas outdoor workers get about 220 SED a year. If indoor workers take one week's vacation in the Mediterranean area the yearly UV dose is increased by 30 - 50 %, and this sun behaviour inevitably results in sunburns. People with UVR-related disorders are expected to reduce their sun exposure. This has been measured in patients recently diagnosed with cutaneous malignant melanoma. A clear reduction was found the first season after diagnosis, but sun exposure increased to higher levels than matched controls after just one year, indicating that even very strong incentives only result in very transient change of sun behaviour.
09:35 – 10:10		Guest Lecture <b>FRS: The XP population in the UK: unexpected clinical features and relationship to molecular defects</b> <i>Prof Alan Lehmann (Brighton)</i> Patients with xeroderma pigmentosum (XP) are deficient in their ability to repair UV damage in their DNA. The UK XP Multi-disciplinary Service was established in April 2010 and we have examined 75 patients for clinical features, DNA repair and molecular defects. Analysis of this large cohort has revealed surprising variability in clinical features of patients, not only between the eight genetically distinct XP groups but also within these groups. The sunburn response, age of onset of skin cancers and neurological abnormalities are all dependent on the precise molecular defect. Those groups associated with neurological abnormalities have an acute and exaggerated sunburn response, whereas those without neurological problems have a normal sunburn response. As an example of variation within one group, two patients mutated in the XPF gene have very mild clinical features (sun sensitivity, but few pigmentary changes and no skin cancers), whereas two others have the very severe combined features of XP and Cockayne Syndrome. These and other examples of unusual genotype-phenotype relationships will be discussed.
10:10 – 10:25	PD02	<b>Clinical and molecular analysis of 13 XP-A patients from the U.K.: genotype-phenotype correlation with prognostic importance</b> <u>M. Sethi</u> , S. Haque, A. Lehmann, S. Mohammed, N. Chandler, D. McGibbon, R. Sarkany and H. Fassih
10:25– 10:45	Break	Exhibition Hall 5
10:45 – 11:00	PD03	<b>A novel automated method to assess photodamaged skin</b> O.S. Osman, <u>K. Naidoo</u> , V. Bataille, S. Jassim, K. Langlands and J. Selway
11:00– 11:15	PD04	<b>Retrospective study of patients with idiopathic solar urticaria: cohort of 45 cases</b> <u>M. Sivaramakrishnan</u> and S. Ibbotson
11:15 – 11:30	PD05	<b>Hydroa vacciniforme associated with persistent Epstein-Barr virus infection in four patients: clinicopathological studies and response to antiviral therapy</b> <u>A. Fityan</u> , R. Sarkany, A. Robson, E. MacMahon, N. Martinez-Alier and H. Fassih
11:30 – 11:45	PD06	<b>Is there a role for filaggrin mutations in the pathogenesis of chronic actinic dermatitis?</b> <u>C.P. Harkins</u> , A. Waters, A. Kerr, L. Campbell, W.H.I. McLean, S.J. Brown and S.H. Ibbotson

Thur 3 July





# British Society for Skin Care in Immunocompromised Individuals

**Date:** Thursday 3rd July

**Time:** 08:50 – 12:30

**Room:** Carron

**Chair:** Prof Catherine Harwood & Dr Nilesh Morar  
Prof Charlotte Proby & Dr David Paige

PROGRAMME		
08:50 – 08:55		Welcome & Introduction by Dr Charlotte Proby
		<b>INTERACTIVE CASE DISCUSSION with Expert panel</b>
09:00 – 09:05	BI01	<b>Cutaneous leishmaniasis while taking adalimumab for psoriasis</b> <u>V.M. Smith</u> and V. Goulden
09:05 – 09:10	BI02	<b>Aspergillosis pneumonia as a fatal complication of recalcitrant severe bullous pemphigoid</b> <u>M.F. Chin</u> , K. May and M.M.U. Chowdhury
09:10 – 09:15	BI03	<b>Too much hair, not enough hair and acne after a kidney transplant: it's not always the drugs</b> <u>R. Atkar</u> and C. Harwood
09:15 – 09:20	BI04	<b>Noduloulcerative skin lesions in an HIV-positive man: an increasingly common presentation of an ancient disease</b> <u>M. Krupiczkojic</u> , P. Goldsmith, R. Cerio, C. Orkin, E. Williams and C. Harwood
09:20 – 09:25	BI05	<b>A rare presentation of graft-versus-host disease 6 years post-liver transplant</b> <u>A. Jamil</u> , T. Desai and M. Muzaffar
09:25 – 09:35		Discussion time
09:35 – 09:40	BI06	<b>Legionella feeleii: A novel organism associated with cutaneous infections in immunocompromised patients</b> <u>S. Verykiou</u> , C. Goodhead and S. Meggitt
09:40 – 09:45	BI07	<b>Granulomatous inflammation associated with common variable immunodeficiency: case report and review of the literature</b> <u>S. George</u> , R. Chee and C. DeGiovanni
09:45 – 09:50	BI08	Rosacea: a rare presentation of immune reconstitution inflammatory syndrome <u>S. Karanovic</u> , S. George, E. Topham and F. Cresswell
09:50 – 09:55	BI09	Papular pruritic eruption of HIV responsive to oral thalidomide <u>A. Wernham</u> and S.-L. Chua
09:55 – 10:05		Discussion time
10:05 – 10:15		Poster round up
10:15 – 11:00	Break	Exhibition Hall 5
11:00 – 11:35		 <p>Guest Lecture <b>Current surgical dilemmas in the management of high risk cutaneous SCC of the head and neck</b> <i>Roger Currie &amp; Carrie Newlands (both BAOMS)</i></p> <p>Roger Currie is a Consultant Oral and Maxillofacial Surgeon from Ayrshire, he is an elected Member of Council of the Royal College of Surgeons of Edinburgh and was involved in the new SIGN guideline on SCC.</p>  <p>Carrie Newlands is a Consultant Oral and Maxillofacial Surgeon from Guildford, and National Skin Surgery Lead for her speciality. She is presently working with the BAD to update the BCC and SCC Guidelines.</p> <p>This talk is given jointly, and discusses the definition of high risk cSCC, the evidence for surgical excision margins and the role of adjuvant radiotherapy to the primary site. Investigation of the regional lymphatics will be explored, including the role of sentinel node biopsy, when to image, and the management of established regional metastasis.</p>
11:35 – 11:45	BI10	<b>Skin cancer after haematopoietic stem cell transplant: is long-term skin cancer surveillance required?</b> <u>S. Chinthapalli</u> , J. McGregor and C. Harwood
11:45 – 11:55	BI11	<b>Adherence to vaccination guidelines in dermatology patients on immunosuppressive therapy: an opportunity for improvement</b> <u>M. Sadlier</u> , C. Sadlier, A. Alani, K. Ahmad, C. Bergin and B. Ramsay

Thur 3 July

11:55 – 12:05	BI12	<b>Risk of skin cancer in patients with inflammatory bowel disease</b> J. Clowry, J. Sheridan, D. Keegan, K. Byrne, H. Comber, S. Deady, G. Cullen, H. Mulcahy, G. Doherty and A. Lally
12:05 – 12:30		AGM
<b>POSTERS</b>		
	BI13	<b>Dermatophytic panniculitis in a postrenal transplant patient</b> M. Arunachalam, M. Galeone, A. Bassi and E. Difonzo
	BI14	<b>An eruption of plaques on the lower leg in an immunocompromised patient</b> P. Trehan, N. Khirwadkar, A. Al-Sharqi and Milli Shah
	BI15	<b>Rosacea-like dermatosis in a patient with X-linked chronic granulomatous disease treated effectively with hydroxychloroquine</b> K.S. Chen and R. Motley
	BI16	<b>Flu vaccination reaudit</b> A. Devine, M. Cole and P. Yesudian
	BI17	<b>Squamous cell carcinoma of the external auditory meatus in an organ transplant recipient: management dilemmas in high-risk tumours</b> A. Lock, J. McGregor and C. Harwood
	BI18	<b>Skin cancer and immunosuppression in long-term renal transplant recipients: a retrospective and case-controlled analysis</b> R.K.Y. Hung, A. Cronin, I. Rebollo Mesa, S. Frame and E.M. Wain
	BI19	<b>Successful treatment of human papilloma virus-induced digital Bowen disease with a combination of acitretin and topical imiquimod</b> A. Jamil and T. Desai
	BI20	<b>Herpes simplex infection masquerading as actinic keratosis and responding to topical 5-fluorouracil therapy</b> P. Gazzani, J. Brockley and A. Ilchysyn
	BI21	<b>Education and awareness of nonmelanoma skin cancer risk in liver transplant patients</b> V. Campbell, J. Cash and N. McDougall
	BI22	<b>Cutaneous leishmaniasis in an immunocompromised patient</b> S. Rajan, S. Robinson, J. Pawade and M.G.S. Dunnill
	BI23	<b>Sun protection behaviour among those on immunosuppressants</b> A.E. Honan, L. Burfield, C.P. Harkins, A. Drummond and S. Fraser
	BI24	<b>Erythema nodosum, fever and joint pain: azathioprine hypersensitivity reaction in patients with inflammatory bowel disease</b> H. Cookson, B. Moriarty, E. Higgins, D. Creamer and S. Walsh
	BI25	<b>Sun awareness education and photoprotective behaviour in immunosuppressed renal disease patients: a questionnaire to assess knowledge and practices</b> J. Wright and P. Hewins
	BI26	<b>Disseminated cutaneous Mycobacterium chelonae and phaeohyphomycosis</b> N. Meah, V. Parris, S. Hickey, M. Chaponda, L. Forsyth and W. Hope
	BI27	<b>Severe cutaneous infection associated with impaired function of myeloid and lymphoid lineages in haematological malignancy</b> E. Seccombe, A. Lee, S.S. Vijeratnam, C.Y. Ung, H. Lotery, M. Jenner and M. Ardern-Jones
	BI28	<b>Mycobacterium abscessus presenting with disseminated cutaneous nodules in an immunosuppressed patient</b> S. Rasool, T. King and P. Woo
	BI29	<b>Destructive cutaneous leishmaniasis in a patient being treated with anti-TNF-</b> R. Gurreri, G. Pistone and M.R. Bongiorno
	BI30	<b>Sitagliptin for severe psoriasis</b> M. Lynch, A.-M. Tobin, T. Ahern, D. O'Shea and B. Kirby

The poster viewing session will take place between 13:00 and 13:30 on Thursday 3rd July

# Continuing Professional Development Session



**Date:** Thursday 3rd July

**Time:** 13:30-17:00

**Room:** Lomond

**Chair:** Dr Graham Sharpe & Dr David Eedy

## PROGRAMME

13:30 – 14:15		Arthur Rook Oration – Introduced by Dr David Eedy <b>The magic and mayhem of human skin resident T cells</b> <i>Dr Rachael Clark (Boston, USA)</i> The healthy skin of an adult contains nearly 20 billion memory T cells, twice as many as are present in the entire circulation. Resident memory T cells (TRM) generated as a result of past infections accumulate in epithelial barrier tissues and provide rapid on-site immune protection against known pathogens. However, TRM aberrantly activated in skin contribute to inflammatory skin diseases and exclusion of TRM is a common way that skin and other epithelial cancers evade immune detection. This presentation will discuss the role of human TRM in healthy skin, inflammatory diseases and skin cancers.
14:15 – 14:45	CPD01	<b>What's new in Tropical Dermatology</b> Dr Nick Beeching (Liverpool)
14:45 – 15:30	Break	Concourse and focus sessions
15:30 – 16:00		Guest Lecture – Introduced by Professor Christopher Bunker <b>The Dark Skin and Photodermatoses</b> <i>Professor Vinod Sharma (New Delhi, India)</i> The dark skin is inherently considered to be less susceptible to damage by ultraviolet light and photodermatoses. In a study 362 patients of photodermatoses with skin types IV and V at New Delhi, PMLE (59.7%) to be commonest followed by CAD (13.8%), collagen vascular disorders (7.7%) and photoaggravated atopic dermatitis (6.1%). actinic lichen planus (ALP) and lichen planus pigmentosus (LPP) in 3.8% patients. Pinpoint papular variant of PMLE was common and actinic prurigo, solar urticaria and hydroa vacciniforme were not observed. The challenges of phototesting in dark skin type IV to VI are yet to be addressed.
16:00 – 16:30	CPD02	<b>What's new in Paediatrics</b> Dr Nerys Roberts (London)
16:30 – 17:00	CPD03	<b>What's new in Photodermatology</b> Dr Sally Ibbotson (Dundee)

## NOTES

Thur 3 July

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

# Focus Sessions

**Date:** Thursday 3rd July  
**Time:** 15:00-15:30  
**Room:** Alsh  
**Chair:** Dr Catherine Stefanato  
 Alopecia Focus Session

## PROGRAMME

15:00 – 15:30	FS1	<b>Invite speaker: Dr David Fenton, MBE</b> This interactive session will present, in a vignette-type format, selected encounters with patients with scarring and non-scarring alopecias. Diagnostic clues and pitfalls, as well as management pearls will be discussed. Clinico-pathological correlation will be emphasised.
---------------	-----	---

**Date:** Thursday 3rd July  
**Time:** 15:00-15:30  
**Room:** Boisdale  
**Chair:** Dr Anthony Bewley  
 'Itch' Focus Session

## PROGRAMME

15:00 – 15:15	FS21	<b>Diagnosis and treatment of itch in the dermatology clinic</b> Dr Frances Lawlor
15:15 – 15:30	FS22	<b>The aetiology of itch</b> Dr Tabi Leslie

**Date:** Thursday 3rd July  
**Time:** 15:00-15:30  
**Room:** Carron  
 Hyperhidrosis Focus Session

## PROGRAMME

15:00 – 15:30	FS3	<b>Top Tips for hyperhidrosis</b> Dr Niall Wilson
---------------	-----	--

## NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

Thur 3 July

# Posters

The posters are situated within the exhibition hall. The poster viewing session will take place during the lunch breaks on Tuesday (even numbered posters) and Thursday (odd numbered posters). All presenting authors have been asked to stand by their posters at this time. There will also be an e-poster display within the exhibition hall.

## Clinicopathological Cases

- P01** **Cutaneous Rosai-Dorfman disease: four diverse clinical presentations, one unifying histological diagnosis**  
S.H. Foo, A. Abdullah, A. Rajasekaran, S. Velangi and M. Maheshwari
- P02** **A case series of pyoderma gangrenosum after deep inferior epigastric perforator-flap breast reconstruction**  
J. Simpson, P. Harris, G. Stamp, S. James, C. Bunker and L. Fearfield
- P03** **Use of *in vivo* reflectance confocal microscopy to monitor response of an amelanotic lentigo maligna to topical treatment with imiquimod**  
A. Alani, M. Sadlier, B. Ramsay and K. Ahmad
- P04** **Trophic ulceration secondary to carpal tunnel syndrome**  
J.L.C. Wong, R. Karumanchery, K. Ngan and L. Stewart
- P05** **Biologics-induced bullous pemphigoid**  
C. Kiely, M. Connolly, R. Hughes, Q. Razali and A.-M. Tobin
- P06** **A case of Birt-Hogg-Dubé syndrome**  
C. Reid and S. Jain
- P07** **Intravenous human immunoglobulin for treatment of folliculitis decalvans**  
N. Ismail, N. Ralph and G. Murphy
- P08** **An unusual case of scar sarcoidosis**  
E.D. Owen, J. Collins and P. Hunasehally
- P09** **Topical steroid-induced Cushing syndrome**  
N. Spierings, T. Stevens and J. Natkunarajah
- P10** **Fifty shades of grey: para-phenylenediamine-induced vitiligo-like depigmentation**  
N. Spierings and J. Natkunarajah
- P11** **Treatment-resistant nodular prurigo that resolved during coincidental treatment with a glucagon-like peptide-agonist**  
R. Hughes, C. Kiely, M. Connolly, J. Gibney and A. Tobin
- P12** **Extreme leucocytosis in metastatic melanoma**  
C. Reid and A. Belgi
- P13** **Acitretin-induced pyogenic granulomas**  
N. Spierings, B. Ho and J. Natkunarajah
- P14** **Pancreatic panniculitis with no pancreatic pathology: where are the 'ghosts'?**  
N. Spierings and J. Natkunarajah
- P15** **Sporotrichoid *Mycobacterium chelonae***  
F. Worsnop, P. Mahendran and J. Natkunarajah

## Education, Training, Service, Audit

- P16** **Skin cancer excision performance in primary and secondary care in Scotland**  
W.Y. Haw, S. Fraser, A. Affleck and A. Holme
- P17** **Commissioning National Health Service dermatology services: what do patients want?**  
P. Fiandeiro and K. Ward
- P18** **Methotrexate-responsive oral lichen planus: an analysis of 28 patients**  
J.C. Steele, V.C.Y. Li, B.P. Rajlawat, E.A.L. Field and P.D. Yesudian
- P19** **A retrospective review of a dedicated psychology-based psychodermatology service**  
A. Mizara, K. Badsha, M. Griffiths and S. McBride
- P20** **Clinical utility of virtual patient follow-up in a tertiary psoriasis service**  
E. Agius, C. Fleming and C. Smith
- P21** **Single-centre, retrospective study of patients with psoriasis referred to a psychology-based psychodermatology service**  
S. Aguilar-Duran, A. Mizara, J. Champagne, K. Badsha, M. Griffiths and S.R. McBride
- P22** **What are the real influences on dermatology outpatient discharge decisions?**  
N.A. Harun, A.Y. Finlay, V. Piguet and S. Salek

- P23** **Is a randomized controlled trial of intralesional corticosteroids for alopecia areata currently feasible? Results of a national clinician survey and observation of current practice in two U.K. teaching hospitals.**  
W. Szczecinska, T.W. Siah, J. Brockley, A.R. Shipman, J.M. Kassim, J. Chalmers, C. Layfield, M. McPhee, H.C. Williams and A.E. Macbeth
- P24** **Dermatology trainee doctor survey: acute general medical on call could endanger patients**  
R. Coelho and N. Levell
- P25** **The innovative electronic Teaching Log: a tool to record teaching and training activity**  
P. McElnay, D. Howard, D. Bakhbakhi, S. Fowweather and J. Sansom
- P26** **Assessment of anxiety and depression associated with psoriasis in a tertiary referral setting**  
R. Lamb, M. Turner, F. Matcham, L. Rayner, A. Simpson, M. Hotopf, J. Barker, C. Smith and K. Jackson
- P27** **A regional audit on the management of primary cutaneous squamous cell carcinoma**  
K.S. Chen and P. Balasubramaniam
- P28** **Cervical screening uptake in a dermatology patient cohort on immunosuppressive agents**  
J. Clowry, I. Callanan, P. Collins, B. Kirby and A. Lally
- P29** **A retrospective analysis of patient characteristics in 63 cases of frontal fibrosing alopecia**  
V.C.Y. Li, P.D. Yesudian and P. Balasubramaniam
- P30** **Regional audit of the nonsurgical management of basal cell carcinomas**  
R.S. Llewellyn and A. Alkali
- P31** **An audit on emergency dermatology activity**  
N. Lee and C. Vlachou
- P32** **Merkel cell carcinoma in Scotland 2000-10**  
A. Matthews, R. Samuel, A. Affleck, M. Darling, S. Fraser, G. Gupta, J. Norris, S. Rajpara, J. Vestey and A. Holme
- P33** **Impact on dermatology patients of an electronic patient record**  
G. Parkins, G. Wylie and J. Leman
- P34** **Review of acute inpatient and general practitioner referrals to our dermatology department**  
G. McIntyre, E. Mack, O. Mulholland and S. Hoey
- P35** **Thalidomide use in dermatology: a multitrust regional audit**  
S. Whitaker, M. Vatve and S. Wahie

## General Dermatology

- P36** Withdrawn
- P37** **Male genital lichen sclerosus and filaggrin**  
T.N. Shim, S.J. Brown, L.E. Campbell, N. Francis, M. Dinneen, D. Hawkins, A. Muneer, S. Minhas, A. Freeman, W.H.I. McLean and C.B. Bunker
- P38** **The Hidradenitis Suppurativa Priority Setting Partnership**  
J.R. Ingram, R. Abbott, M. Ghazavi, A. Alexandroff, M. McPhee, T. Burton and T. Clarke
- P39** **Subtypes of severe acne vulgaris in a prospective multicentre study in the U.K.**  
A.A. Navarini, D. Burden, A. Layton, V. Bataille, S. Walton, C.H. Smith, J.N. Barker and The Acne Genetic Study Group
- P40** **Prevalence of metabolic syndrome, insulin resistance and subatherosclerosis in patients with chronic plaque psoriasis in India: a hospital-based case-control study**  
S.K. Kothiwala, N. Khanna, V.K. Sharma, N. Tondon, N. Naik, S. Sharma and V. Srinivas
- P41** **Comparison of the clinicoepidemiological profiles of childhood vitiligo and adult vitiligo: an analysis of 1325 Indian patients**  
J. Kaur and A.J. Kanwar
- P42** **Frontal fibrosing alopecia in premenopausal women: a review of 16 cases**  
G. Parkins and S. Holmes
- P43** **Early clinical and pathological cutaneous features of chronic graft-versus-host disease**  
M. Lynch, A. Pagliuca, G. Mufti, J. Salisbury and T. Basu



- P44** **How people with acne decide whether their treatment is working**  
K. Warburton, H. Whitehouse, R. El-Naes, A. Eady and A. Layton
- P45** **Persistence of viable *Mycobacterium leprae* after multidrug therapy in patients with multibacillary leprosy. Is this the missing link in leprosy eradication?**  
T. Narang, S. Dogra and U.N. Saikia
- P46** **Management of morphea: results of a national survey of U.K. clinicians**  
K.L. Warburton, M.J. McPhee, L.J. Savage, A.E. Honan, R. Montgomery, M. Ghazavi, D. Torley, K. Shams and J.R. Ingram
- P47** **Self-improving collodion baby: the dynamic stratum corneum**  
K. Muttardi, F.M. Tatnall, M. Murdoch A.E. Martinez and K. Batta
- P48** **Connexin 30 mutations can lead to a clinical phenotype resembling pachyonychia congenita**  
G. Hale, N. Wilson, F. Smith, M. Schwartz and M. Zamiri
- P49** **Young patients with complicated perianal and peristomal predicaments**  
Z.Z.N. Yiu, F.R. Ali and C.C. Lyon
- P50** **Leprosy: is it being misdiagnosed?**  
F. Ali, A.A. Atwan, J. Vyas and V. Piguet
- P51** **Enhanced expression of interleukin (IL)-17, IL-10 and IL-1 in hidradenitis suppurativa**  
G. Kelly, C. Sweeney, R. Fitzgerald, A. Lally, A.-M. Tobin and B. Kirby
- P52** **Plasma cell vulvitis: a series of eight cases**  
G. Dawn, D. Caruana, V. Harper and F. Gallagher
- P53** ***Neoscytalidium dimidiatum*: a tropical mould of mankind and mangoes**  
J. Powell and J. Gach
- P54** **A clinical and molecular analysis of scalp folliculitis and folliculitis decalvans**  
A. Lee, S.-Y. Cho, T.-S. Yam and M. Arden-Jones
- P55** **Cutaneous manifestations of leucocyte adhesion deficiency-1**  
R. Sarangal, S. Dogra and A.J. Kanwar
- P56** **A pilot study comparing the impact of acne on the quality of life of women with persistent acne vs. late-onset acne**  
S. Ladbrooke, M. Waterman, R. El-Naes, C. Finch, E. Fryatt, V. Allgar, A. Eady and A. Layton
- P57** **Delusional infestation carries mortality: a report of two cases**  
S. Nasir, A. Ahmed, L. Holloway, R. Meyrick-Thomas and A. Bewley
- P58** **Cutaneous side-effects of antihepatitis C treatment: the U.K. experience**  
E. Orrin, K. Agarwal, A. Barnabas and S. Walsh
- P59** **A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres**  
P. Mahar, J. Wasiak, B. Hii, H. Cleland, D. Watters, D. Gin and A. Spinks
- P60** **Factors associated with hair loss in women of African descent living in London, U.K.: findings of a cross-sectional study**  
O.E. Dadzie and A. Salam
- P61** **Pyoderma gangrenosum: clinical features concealed by vacuum-associated closure**  
R. Hellen, L. Jennings and S. Collins
- P62** **New missense mutation in the fumarate hydratase gene associated with hereditary leiomyomatosis and renal cell cancer syndrome**  
N. Bansal, A. Cuthbert, E. Woodward and M. Kaur
- P67** **National survey of patients with hereditary basal cell naevus syndrome: psychological impact, treatment and care**  
F.R. Ali, N.J. Collier, G. Evans, M. Costello, S. Webster and J.T. Lear
- P68** **Treatment of extensive eyelid basal cell carcinoma with vismodegib as an alternative to Mohs micrographic surgery**  
L. Wujanto, D. Basak, A. Milligan, G. Stewart and E. Seaton
- P69** **Are general practitioners in areas of higher skin cancer incidence better at diagnosing skin cancer?**  
D. Keith, A. Ives, T. Jones, D. de Berker and J. Verne
- P70** **Nail unit squamous cell carcinoma in people with immune suppression**  
E. Ormerod and D. de Berker
- P71** **Two cases of mycosis fungoides palmaris et plantaris**  
A. Matthews, S. Holmes, B. Jackson and D. Bilstrand
- Therapy**
- P72** **Isotretinoin and peanut allergy: what's all the fuss about?**  
N. Spierings, J. Natkunarajah, A. Bansal and L. Ostlere
- P73** **Cognitive behavioural therapy for two patients with delusional infestation: a new concept with a positive outcome**  
R. Shah, A. Ahmed and A. Bewley
- P74** **Cutaneous adverse reactions to tyrosine kinase inhibitors in a cohort of patients treated for chronic myeloid leukaemia**  
A. Sears, E. Orrin, J. Salisbury, G. Mufti, H. De Lavallade and T. Basu
- P75** **Retrospective study on the effect of conventional therapy, antitumour necrosis factor agents and ustekinumab on weight, body mass index and waist circumference in patients with chronic plaque psoriasis**  
L. Patricia, S. Gupta, M. Clement and K. Watson
- P76** **Clinical outcomes of patients receiving topical treatments for pyoderma gangrenosum: a prospective observational study**  
F. Craig, N. Greenlaw, E. Harrison, J. Mason, E. Mitchell, J. Norrie, A. Ormerod, K. Thomas, H. Williams and Stop Gap Trial Group Collaborators
- P77** **Safety of systemic therapies for psoriasis on reproductive potential and outcomes**  
Z.Z.N. Yiu, R.B. Warren and C.E.M. Griffiths
- P78** **Efficacy of photodynamic therapy for treatment of basal cell carcinoma in the elderly**  
N. Collier, F. Ali and J. Lear
- P79** **Noncultured epidermal cell suspension and dermal fat grafting in a single sitting for the reconstruction of an irregular, atrophic and depigmented forehead scar: an innovative approach**  
R. Sarangal, S. Dogra, S. Yadav and A. Sakral
- P80** Withdrawn
- P81** **Daptomycin for the treatment of diabetic foot infections: 6-year clinical experience from the EU-CORESM registry**  
A. Gonzalez-Ruiz, S. Hedderwick, M. Allen, A. Tamta, C. Andrews and R.A. Seaton
- P82** **Efficacy and safety of intralesional *Mycobacterium w* vaccine and cryotherapy in the treatment of refractory extragenital warts: a randomized open-label comparative study**  
S. Dogra, A. Kumar and A.J. Kanwar
- P83** **Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis**  
J. Powell, F. Woodhead, P. Perkins, N. Brearley and J. Gach
- P84** **Alpha-1-antitrypsin deficiency panniculitis treated with enzyme replacement**  
S. Rasool, K. Harman, M. Bamford and G. Saldanha
- P85** **Rivaroxaban: a novel treatment for livedoid vasculopathy**  
T. Tull, B. Hunt and R. Groves
- P86** **The effect of a complex emollient cream containing 5% urea, ceramide 3 and lactic acid, compared with a simple emollient, on the skin barrier in older people with dry skin**  
S. Danby, K. Brown, T. Higgs-Bayliss, J. Chittock and M. Cork
- Richard B. Stoughton Memorial Upregulation of Inhibitory Signaling Receptor Programmed Death Marker-1 (PD-1) in Disease Evolution from Cutaneous Lymphoid Dyscrasias to Mycosis Fungoides and Sezary's syndrome**  
G.H. Nguyen, X. Wang, A.H. Yassin, C.M. Magro

## Skin Cancer

- P63** **Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur**  
A. Wernham, F. Shah, R. Amel-Kashipaz, M. Cobbold and J. Scarisbrick
- P64** **Cables1, male genital lichen sclerosus and penile cancer**  
T.N. Shim, N. Francis, D. Peston, S. Phan, S. Minhas, A. Muneer, M. Dinneen, A. Freeman and C.B. Bunker
- P65** **Experience of management of Sézary syndrome in a regional cutaneous T-cell lymphoma centre**  
P. Laws, R. Alhusayen and N. Shear
- P66** **Rates of recurrence and metastases of high-risk cutaneous squamous cell carcinoma: a 5-year single-institution study**  
P. Subramanian, B. McDonald and F. Ismail

# Hot Topics

This is a new initiative for the 94th Annual Meeting. They will be semi-informal set-up taking place in two designated areas within the Exhibition Hall 5 during breaks. These are highlighted as HT1 and HT2 on the exhibition plan.

## TUESDAY 1st JULY – morning break

10:45 – 11:15	HT1	<b>Urticaria - what is new?</b> Dr Tabi Leslie
10:45 – 11:15	HT2	<b>Reasons for our New Clinical Classification of Onychomycosis</b> Dr Robert Baran

## TUESDAY 1st JULY – afternoon break

15:45 – 16:15	HT1	<b>Hot historical Dermatologists: who was the greatest?</b> <i>A story of baldness and facial hair</i> Dr Nick Levell
15:45 – 16:15	HT2	<b>Drug Rashes</b> Dr Mike Ardern-Jones & Dr Sarah Walsh

## WEDNESDAY 2nd JULY – afternoon break

16:15 – 16:45	HT1	<b>HPV vaccination for men</b> Dr Bill Porter
16:15 – 16:45	HT2	<b>Changes in Primary &amp; Secondary Interface with new commissioning</b> Dr Stephen Kownacki

## THURSDAY 3rd JULY – morning break

10:30 – 11:00	HT1	<b>Outcome Measures for Dermatology Clinical Trials</b> Prof Kim Thomas & Dr Joanne Chalmers
10:30 – 11:00	HT2	<b>What's hot in psychodermatology</b> Dr Anthony Bewley & Dr Andrew Affleck

IT TAKES  
**SEVEN**  
SKIN CANCER APPEAL



# HELP US LEAD THE FIGHT AGAINST **SKIN CANCER**

'IT TAKES 7' IS A FUNDRAISING CAMPAIGN BY THE BRITISH SKIN FOUNDATION TO RAISE MONEY FOR VITAL RESEARCH INTO SKIN CANCER

 VISIT [WWW.ITTAKESSEVEN.ORG.UK](http://WWW.ITTAKESSEVEN.ORG.UK) TO GET INVOLVED AND PLEASE HELP US SPREAD THE WORD

# Exhibition Plan





## EXHIBITION PLAN HALL 5 SECC GLASGOW

Stand No. Company Name

- D14 AbbVie
- E22 Albert Waeschle
- C20 Almirall Ltd
- E24 Archimedes Pharma
- C24 Athrodax Healthcare International Ltd
- E18 BADBIR
- E47 BAD Historical Collection
- A1 BAD Journals
- A10 Beiersdorf UK Ltd
- A3 Bio-Diagnostics
- E32 Blink Medical Ltd
- A17 British Skin Foundation
- E20 Brymill Cryogenic Systems (UK) Ltd
- A16 Celgene Ltd
- B4 Circle Healthcare
- A20 Clinical Services Unit
- D30 Clinique Laboratories LLC
- D50 CliniSupplies
- A2 Community Dermatology & IFD
- D40 Crawford Healthcare
- E46 Cynosure UK Ltd
- A26 Dermal Laboratories Ltd
- A18 Doctors.net.uk
- B10 Diagenics Ltd
- E40 Dr. Hönle Medizintechnik GmbH
- D24 Fagron UK Ltd
- A19 First Medical
- D32 Galderma UK Ltd
- E48 General Medicine Group
- C2 Hospira UK Ltd
- E44 Humanmed UK Ltd
- D28 Intrapharm Laboratories Ltd
- B30 Janssen
- D29 Johnson & Johnson Ltd
- A2a Kent Pharmaceuticals Limited
- B50a La Roche-Posay
- E30 LEO Pharma
- B12 LD Path Group
- B2 medac GmbH
- A24 Meda Pharmaceuticals Ltd
- E42 Molnlycke Health Care
- B16 MSD
- C30 Novartis Pharmaceuticals UK Ltd
- B1 Pern Consumer Products Ltd
- B14 Pierre Fabre Dermo-Cosmétique
- E21 RB UK Commercial Limited
- D20 Roche Products Ltd
- E34 Schuco
- B50b SkinCeuticals

R26





**Stand No. Company Name**

- C1 Sobi Ltd
- E16 Special Interest Groups
- D26 Spectrum
- A14 Spirit Healthcare Ltd
- B20 Stiefel a GSK Company
- D10 Thornton and Ross Ltd
- B18 Typharm Dermatology Ltd
- B50c Vichy Dermablend
- A23 Wisepress Medical Bookshop

**Stand No. Company Name**

- PSG3 Allergy UK
- PSG6 Alopecia UK
- PSG5 British Association of Skin Camouflage
- PSG10 Caring Matters Now
- PSG8 Changing Faces
- PSG15 Ehlers Danlos Support UK
- PSG4 Ichthyosis Support Group
- PSG14 Latex Allergy Support Group
- PSG7 National Eczema Society
- PSG2 SIGN
- PSG9 Skin Camouflage Network
- PSG12 Skin Conditions Campaign Scotland
- PSG11 The Hyperhidrosis Support Group
- PSG1 UK Dermatology Clinical Trials Network
- PSG14 UK Mastocytosis Support Group
- PSG13 XP Support Group

# Exhibitor Directory

## AbbVie – D14

Abbott House, Vanwall Business Park,  
Maidenhead, Berkshire SL6 4XE  
TEL: 01628 644300  
WEBSITE: www.abbvie.co.uk  
EMAIL: m.fisher@abbvie.com  
CONTACT NAME/S: Mark Fisher

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.

## Albert Waeschle – E22

Unit 11 Balewa Close, Creekmoor Industrial Estate,  
Creekmoor, Poole BH17 7DB  
TEL: 01202 601177  
WEBSITE: www.aw-online.com  
EMAIL: john@albertwaeschle.com  
CONTACT NAME/S: John Hall

Albert Waeschle has been supplying the Dermoscopy profession for over thirty years. Our first class technical knowledge has enabled us to develop products in conjunction with leading specialists to ensure superb product performance.

## Almirall Ltd – C20

1 The Square, Stockley Park, Uxbridge UB11 1TD  
TEL: 020 7160 2500  
EMAIL: slavka.hvilova@almirall.com  
CONTACT NAME/S: Slavka Hvilova

Almirall is an international pharmaceutical company with the primary purpose to provide valuable medicines to you and future generations. With headquarters in Barcelona, Spain, Almirall have a strong international interest in Dermatology. Almirall research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing.

## Archimedes Pharma – E24

250 South Oak Way, Green Park, Reading, Berkshire RG2 6UG  
TEL: 0118 931 5060  
WEBSITE: www.archimedespharma.com  
EMAIL: robertbrewster@archimedespharma.com  
CONTACT NAME/S: Robert Brewster

Archimedes Pharma is an International speciality pharmaceutical company providing novel and advanced treatments to address unmet needs for people living with serious or life-threatening chronic and debilitating illness in oncology, pain and critical care.

## Athrodax Healthcare International Ltd – C24

Hawthorn Business Park, Drybrook, Gloucester GL17 9HP  
TEL: 01594 544 440  
FAX: 01594 545 800  
WEBSITE: www.athrodax.co.uk  
EMAIL: sales@athrodax.co.uk  
CONTACT NAME/S: Mrs Eve Hall

Athrodax, and our partner company Waldmann, look forward to presenting our 5002 UV Phototherapy cabin along with the 182 modular system. We will also be unveiling the innovative Skintrek device, using the latest computer optic technology for digital phototherapy, as well as our new Video Dermoscopy system.

## BADBIR – E18

British Association of Dermatologists  
Biologic Interventions Register (BADBIR)  
The University of Manchester, Rutherford House (Unit 1 FF),  
Manchester Science Park, 40 Pencroft Way, Manchester, M15 6SZ  
TEL: 0161 306 1896  
FAX: 0161 306 1912  
EMAIL: badbir@manchester.ac.uk  
WEBSITE: www.badbir.org  
CONTACT: Kathleen McElhone, BADBIR Coordinator

The BADBIR is a national register of patients receiving therapy for the treatment of moderate to severe psoriasis in the UK. Data is collected on patients treated with biologics or other systemic treatments (for control purposes). The primary aim of the register is to monitor the safety of biologic agents.

## BAD Historical Collection – E47

Willan House, 4 Fitzroy Square,  
London W1T 5HQ  
EMAIL: frances.humphreys@swft.nhs.uk  
CONTACT: Dr Frances Humphreys

## BAD Journals – A1

Willan House, 4 Fitzroy Square, London W1T 5HQ  
TEL: 0207 391 6346  
CONTACT: John Caulfield, Editorial Manager  
EMAIL: john@bad.org.uk  
WEBSITE: www.bad.org.uk

## Beiersdorf UK Ltd – A10

2010 Solihull Parkway,  
Birmingham Business Park, Birmingham B37 7YS  
TEL: 0121 329 8800  
WEBSITE: www.Eucerin.com  
EMAIL: Eve.Townley@beiersdorf.com  
CONTACT NAME/S: Evelynne Townley

For more than 100 years Eucerin has been pioneering dermatological science and innovation, resulting in recommendations by dermatologists and pharmacists worldwide. We are committed to products that work, meeting the skin's requirements throughout life. Helping to give individuals the feeling of confidence that comes from healthy, radiant looking skin.

## Bio-Diagnostics – A3

Upton industrial Estate, Rectory Road,  
Upton upon Severn, Worcester WR8 0LX  
TEL: 01684 592262  
WEBSITE: www.bio-diagnostics.co.uk  
EMAIL: enquiries@bio-diagnostics.co.uk  
CONTACT NAME/S: Jane Hassell / Lee Bellis

Bio-Diagnostics have the most extensive range of Patch Test Allergens, Chambers and consumables for Contact Dermatitis in the UK. Bio-Diagnostics have been the exclusive UK distributor for TROLAB Patch Test Allergens and FINN CHAMBERS for over 30 years and more recently the ALLERGEAZE range of Patch Test Allergens and consumables.

## Blink Medical Ltd – E32

1320 Solihull Parkway, Birmingham Business Park, Birmingham B37 7YB  
TEL: 0121 386 8433  
WEBSITE: www.blinkmedical.com  
EMAIL: sales@blinkmedical.com  
CONTACT NAME/S: Roger Tyler – Managing Director

Blink Medical was established in 2004 as the world's first dedicated manufacturer of high quality, single use surgical instruments. We supply instrumentation to many of the UK's leading dermatology departments and with a worldwide distribution network, covering 15 countries we are leaders in design, development and manufacture of fine instrumentation and customised instrument sets. Visit us at stand E32.

## British Skin Foundation – A17

Willan House, 4 Fitzroy Square, London W1T 5HQ  
TEL: 0207 391 6341  
WEBSITE: www.britishskinfoundation.org.uk  
Email: admin@britishskinfoundation.org.uk

The British Skin Foundation is the only UK based charity dedicated to funding research into all skin diseases.

## Brymill Cryogenic Systems (UK) Ltd – E20

54 Mayfield Ridge,  
Basingstoke RG22 4RS  
TEL: 01256 841045  
FAX: 01256 350330  
WEBSITE: www.brymill.co.uk  
EMAIL: sales@brymilluk.com  
CONTACT NAME/S: Steve Williams

Brymill Cryogenic Systems has been the world leader in the design and manufacture of the Cryosurgical equipment for over 40 years. Brymill UK now supplies a wider range of quality products including Ethicon Sutures, Electrosurgery, HeadLights, Binocular Loupes, Dermatoscopes, Single Use Disposable Instruments, Woundcare Products and Smoke Evacuation systems. And introducing the Swift Microwave Generator.



## Celgene Ltd – A16

1 Longwalk Road, Stockley Park, Hillingdon UB11 1DB

TEL: +44 (0) 208 831 8300

WEBSITE: [www.Celgene.co.uk](http://www.Celgene.co.uk)

CONTACT NAME/S: Tim Shaw

Celgene Corporation is a global biopharmaceutical company that is helping healthcare providers address serious conditions, such as cancer and immune-inflammatory diseases. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide

## Circle Healthcare – B4

Nottingham NHS Treatment Centre,

Queen's Medical Centre Campus

Lister Road, Nottingham NG7 2FT

TEL: 01159 705800

WEBSITE: [www.circlepartnership.co.uk](http://www.circlepartnership.co.uk)

EMAIL: [nikki.lucas@circlepartnership.co.uk](mailto:nikki.lucas@circlepartnership.co.uk)

CONTACT NAME/S: Nikki Lucas

Our mission is to run great hospitals dedicated to our patients. By putting doctors and nurses in charge of our hospitals, making all employees owners, empowering our people to go the extra mile for our patients, combining clinical excellence with five-star hospitality. Because for our patients, 'good enough' never is.

## Clinical Services Unit – A20

Willan House, 4 Fitzroy Square,

London W1T 5HQ

TEL: 020 7391 6085

CONTACT: Tania von Hospenthal

EMAIL: [clinical@bad.org.uk](mailto:clinical@bad.org.uk)

WEBSITE: [www.bad.org.uk](http://www.bad.org.uk)

## Clinique Laboratories LLC – D30

73 Grosvenor Street, London W1K 3BQ

TEL: 0870 034 6955

WEBSITE: [www.clinique.co.uk](http://www.clinique.co.uk)

EMAIL: [jucox@estee-lauder.co.uk](mailto:jucox@estee-lauder.co.uk)

CONTACT NAME/S: Julia Cox

Allergy tested, 100% fragrance free, dermatologist developed

## CliniSupplies – D50

Qualitas House, 100 Elm Grove Road,

Harrow, Middlesex, HA1 2RW

TEL: 44 (0) 208 420 9125

WEBSITE: [www.clinisupplies.co.uk](http://www.clinisupplies.co.uk)

EMAIL: [info@clinisupplies.co.uk](mailto:info@clinisupplies.co.uk)

CONTACT NAME/S: Johnny Levett

Clinisupplies wound and skin care range is designed for patients managing dermatological skin conditions, wounds and venous diseases. Get wrapped up in comfort with Clinifast coloured garments for kids suffering from eczema, dermatitis, psoriasis and other skin diseases. Check out our range of tapes and dressings as well as Clinifast and Clinigrip tubular bandages. Ask us about our popular CliniDUO40 hosiery for venous leg ulcers.

Established in 2000, Clinisupplies is a UK based medical devices company specialising in the manufacturing and marketing of products for the primary and secondary healthcare sectors.

## Community Dermatology & IFD – A2

Willan House, 4 Fitzroy Square, London W1T 5HQ

TEL: 0207 391 6346

CONTACT: John Caulfield, Editorial Manager

EMAIL: [john@bad.org.uk](mailto:john@bad.org.uk)

WEBSITE: [www.bad.org.uk](http://www.bad.org.uk)

## Crawford Healthcare – D40

King Edward Court, King Edward Road, Knutsford, Cheshire WA16 0BE

TEL: 01565654920

WEBSITE: [www.crawfordhealthcare.com](http://www.crawfordhealthcare.com)

EMAIL: [Stephanie.young@crawfordpharma.com](mailto:Stephanie.young@crawfordpharma.com)

CONTACT NAME/S: Stephanie Young

Crawford Healthcare, is a supplier of dermatology and woundcare products covering a broad range of skin conditions. We are dedicated to developing and providing innovative treatment solutions to care and repair the skin, helping our bodies to maintain our number one natural defence system.

## Cynosure UK Ltd – E46

The Old Barn Offices, Lower Mount Farm,

Long Lane, Cookham, Berkshire SL6 9EE

TEL: 01628 522 252

WEBSITE: [www.cynosureuk.com](http://www.cynosureuk.com)

EMAIL: [jenny@cynosureuk.com](mailto:jenny@cynosureuk.com)

CONTACT NAME/S: Jenny Flood

Cynosure UK is a direct UK Subsidiary of Cynosure Inc, recently acquiring Palomar Medical. Our market leading laser products treat hair removal in all skin types, tattoo removal, epidermal and dermal pigmented lesions, vascular malformations, plus invasive treatments including laser lipolysis, hyperhidrosis, surgical and non-surgical cellulite clearance, fractional rejuvenation.

## Dermal Laboratories Ltd – A26

Tatmore Place, Gosmore, Hitchin, Herts SG4 7QR

TEL: 01462 45 88 66

WEBSITE: [www.dermal.co.uk](http://www.dermal.co.uk)

EMAIL: [info@dermal.co.uk](mailto:info@dermal.co.uk)

CONTACT NAME/S: Mr Henrik Pyff

For over 50 years Dermal has been developing highly effective, yet cosmetically elegant treatments for application to the skin. It is the performance of the whole formulation that makes the difference.

We remain committed to building on our history of successful topical innovation and supporting dermatology for the benefit of future generations.

Hear our exciting latest news at stand A26

## Diagenics Limited – B10

South House 3, Bond Avenue, Bletchley,

Milton Keynes MK1 1SW

TEL: 01908 376376

WEBSITE: [www.diagenics.co.uk](http://www.diagenics.co.uk)

EMAIL: [info@diagenics.co.uk](mailto:info@diagenics.co.uk)

CONTACT NAME/S: Jim Khambatta/Sue Haritou

Diagenics will be showing the truest patch test system, which allows the rapid application of 35 pre-dispensed patches and patchprotect to ensure the security of application of the chambers. Information about our large range of skin prick test solutions will be available.

## Doctors.net.uk – A18

90 Park Drive, Milton Park, Abingdon OX14 4RY

TEL: 01235 828400

WEBSITE: [www.Doctors.net.uk](http://www.Doctors.net.uk)

EMAIL: [laura.knox@mess.doctors.org.uk](mailto:laura.knox@mess.doctors.org.uk)

CONTACT NAME/S: Laura Knox

Doctors.net.uk is the largest and most active online professional network for all UK doctors. Doctors are provided with a range of free services including an email service, clinical forums, accredited education and medical news which helps you to keep up to date and to easily maintain your continuing professional development (CPD).

## Dr. Höhle Medizintechnik GmbH – E40

Viktor-Frankl-Strasse 20, 86916 Kaufering, Germany

TEL: 0049-8191-3055530

WEBSITE: [www.drhoenle.de](http://www.drhoenle.de)

EMAIL: [medizin@drhoenle.de](mailto:medizin@drhoenle.de)

CONTACT NAME/S: Petra Kleinhans / Natalie Marek

Dr. Höhle Medizintechnik GmbH is known in the world as a authoritative manufacturer of

- UV therapy systems
- Iontophoresis devices

for the dermatology field. In addition to diagnostic systems, the range of products includes UV radiation devices for clinics and medical practices as well as devices for home therapy.

## Fagron UK Ltd – D24

1st Floor, 1 Pink Lane, Newcastle-upon-Tyne NE1 5DW

TEL: 0845 652 2525

CONTACT: Deborah Johnson

EMAIL: [deborah.johnson@fagron.co.uk](mailto:deborah.johnson@fagron.co.uk)

## First Medical – A19

1.10 Challenge House, Sherwood Drive, Bletchley, Milton Keynes MK3 6PD

TEL: 01908 533245

CONTACT: Lawrence Alexander

EMAIL: [Lawrence.Alexander@first-medical.co.uk](mailto:Lawrence.Alexander@first-medical.co.uk)

WEBSITE: [www.first-medical.co.uk](http://www.first-medical.co.uk)

First Medical Staffing Solutions are the leaders in Dermatology Solutions for the NHS Hospitals. If you are a dermatologist and interested in a variety of full time, part time or ad hoc opportunities please register with us today!

Or if your dermatology department could use extra help, please visit our stand.



### **Galderma UK Ltd – D32**

1st Floor Meridien House, 69-71 Clarendon Rd, Watford WD17 1DS

TEL: 01923 208950

WEBSITE: [www.galderma.co.uk](http://www.galderma.co.uk)

EMAIL: [info.uk@galderma.com](mailto:info.uk@galderma.com)

CONTACT NAME/S: Charlotte Berry/Jan Speller

Galderma is a global leading pharmaceutical company specialising in research, development and marketing of innovative medical solutions in dermatology. Galderma's investments in R&D, extensive product portfolio, global presence and expertise in three segments (prescription drugs, self-medication products, aesthetic and corrective medical solutions) contribute to maintaining its strong leadership in dermatology.

### **General Medical Group – E48**

Devon House, Ground Floor East, 58-60 St. Katharine's Way, London E1W 1LB

TEL: +44(0)2074561450

WEBSITE: [www.generalmedicinegroup.co.uk](http://www.generalmedicinegroup.co.uk)

EMAIL: [nicolahumroy@generalmedicinegroup.co.uk](mailto:nicolahumroy@generalmedicinegroup.co.uk)

[ryanhalliday@generalmedicinegroup.co.uk](mailto:ryanhalliday@generalmedicinegroup.co.uk)

CONTACT NAME/S: Ms Nicola Humroy and Mr Ryan Halliday

General Medicine Group is the only specialist Medicine doctors' recruitment consultancy in the UK. Passionate about our work and committed to being the best healthcare recruitment partner, finding and placing the best doctors and thus delivering the best patient care. We specialise in the placement of Consultant Dermatologists throughout the UK.

### **Hospira UK Limited – C2**

Queensway, Royal Leamington Spa, Warwickshire CV31 3RW

EMAIL: [darren.clarkson@hospira.com](mailto:darren.clarkson@hospira.com)

CONTACT: Darren Clarkson

### **Humanmed UK Ltd – E44**

19 Birchwood Road, Wilmington, Kent DA2 7HF

TEL: 01322 668426

EMAIL: [colin@humanmeduk.com](mailto:colin@humanmeduk.com)

CONTACT: Colin Pyne

### **Intrapharm Laboratories Ltd – D28**

First floor offices, The Granary, The Courtyard Barns, Choke Lane

Cookham Dean, Maidenhead, Berkshire, SL6 6PT

TEL: 01628 481075

WEBSITE: [www.intrapharmlabs.com](http://www.intrapharmlabs.com)

EMAIL: [SunilS@intrapharmlabs.com](mailto:SunilS@intrapharmlabs.com)

CONTACT NAME/S: Sunil Shaunak

Intrapharm have re-launched Terra-Cortril Ointment for exudative and secondarily infected eczema including atopic eczema, primary irritant dermatitis, allergic and seborrhoeic dermatitis. Terra-Cortril is a combination of two components – 3% oxytetracycline and 1% hydrocortisone. It does not contain any preservatives. Please visit our stand D28.

### **Janssen – B30**

50-100 Holmers Farm Way, High Wycombe, Bucks HP12 4EG

TEL: +44 (0) 1494 567 831

WEBSITE: [www.janssen.co.uk](http://www.janssen.co.uk)

EMAIL: [jrankin4@its.jnj.com](mailto:jrankin4@its.jnj.com)

CONTACT NAME/S: Jordan Rankin

At Janssen, we are dedicated to addressing and solving some of the most important unmet needs of our time in immunology, oncology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world

### **Johnson & Johnson Ltd – D29**

Foundation Park, Roxborough Way, Maidenhead SL6 3UG

TEL: 01628 822222

WEBSITE: [www.jnj.com](http://www.jnj.com)

We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people

### **Kent Pharmaceuticals Ltd – A2a**

Joshna House, Crowbridge Road, Ashford, Kent TN24 0GR

TEL: 0845 437 5565

WEBSITE: [www.kentpharm.co.uk](http://www.kentpharm.co.uk)

EMAIL: [jason.webb@kentpharm.co.uk](mailto:jason.webb@kentpharm.co.uk)

CONTACT NAME/S: Diana Leary / Darren Wilding

Kent Pharmaceuticals are the sole UK distributor for "Safe Inject" a single use, local anaesthetic cartridge syringe system.

Safe Inject is CE marked for general medical use and is fully compliant with the EU directive 7318/10 & 8491/10 for safer sharps that ban's the recapping of needles.

### **La Roche-Posay – B50a**

La Roche-Posay, L'Oréal UKI Ltd, 255 Hammersmith Road, London W6 8AZ

TEL: 0800 055 6822

WEBSITE: [www.laroche-posay.co.uk](http://www.laroche-posay.co.uk)

EMAIL: [contact@laroche-posay.co.uk](mailto:contact@laroche-posay.co.uk)

CONTACT NAME/S: Maik Lepatey, Jennie Flatt

Recommended by dermatologists worldwide, La Roche-Posay presents a comprehensive range of skincare solutions with proven efficacy and tolerance, suitable for all skin types, even sensitive. Our product range features carefully selected, highly concentrated active ingredients and unique La Roche-Posay Thermal Spring Water, renowned for its soothing and anti-oxidant properties.

### **LEO Pharma – E30**

Horizon, Honey Lane, Hurley, Berkshire, SL6 6RJ

TEL: 01844 347333

WEBSITE: [www.leo-pharma.co.uk](http://www.leo-pharma.co.uk)

EMAIL: [general.uk@leo-pharma.com](mailto:general.uk@leo-pharma.com)

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions.

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of R&D to delivering products and solutions to people with skin conditions.

LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide. UK/IE/2000/10229 April 2014

LEO® © LEO, DATE OF PREPARATION: April 2014, ALL LEO TRADEMARKS

### **LD Path Group – B12**

Office 8, 50 Belsize Square, Belsize Park, London NW3 4HN

TEL: 0207 435 9099

WEBSITE: [www.ldpath.com](http://www.ldpath.com)

EMAIL: [Operations@ldpath.com](mailto:Operations@ldpath.com)

CONTACT NAME/S: Antoine Deroide, Cameron Niven, Sanjit Lallie

LD Path Group is a leader in the histopathology industry offering a flat fee structure (including special stains, immunocytochemistry, courier and billing) and a turnaround time of 24-48h. All cases are reported by specialist histopathologists who hold a consultant position in a leading NHS hospital.

### **Meda Pharmaceuticals Ltd – A24**

Skyway House, Parsonage Road, Takeley, Bishops Stortford CM22 6PU

TEL: 0845 460 0000

WEBSITE: [www.medapharma.co.uk](http://www.medapharma.co.uk)

EMAIL: [info@medapharma.co.uk](mailto:info@medapharma.co.uk)

CONTACT NAME/S: Fiona Betts

MEDA is one of the top 50 pharmaceutical companies in the world. In the UK we currently have over 70 products, including many well known prescription, pharmacy and cosmetic brands. Our ever-expanding product portfolio covers a wide range of treatment areas from allergy, cardiology and dermatology, to oncology and sexual health.

### **medac GmbH – B2**

Scion House, Stirling University Innovation Park, Stirling FK94NF

TEL: 01786 458086

WEBSITE: [www.medac-uk.co.uk](http://www.medac-uk.co.uk)

EMAIL: [info@medac-uk.co.uk](mailto:info@medac-uk.co.uk)

CONTACT NAME/S: Lauren Addison

medac GmbH is a privately owned German company founded in 1970. medac mainly promotes the development and marketing of therapeutics in the field of autoimmune diseases. Metoject is injectable methotrexate used in the treatment of severe psoriasis. Please come to stand B2 for more information.

### **Molnlycke Health Care – E42**

Molnlycke Health Care, Arenson Centre, Arenson Way, Dunstable, Bedfordshire LU5 5UL

TEL: 0870 6060766

WEBSITE: [www.molnlycke.co.uk](http://www.molnlycke.co.uk)

EMAIL: [info.uk@molnlycke.com](mailto:info.uk@molnlycke.com)

CONTACT NAME/S: Kieran Gormley

Molnlycke Health Care is one of the world's leading providers of single-use surgical and wound care products. We actively work with our customers to provide them with both products and services that will help them manage the challenges they face. For more information on Epaderm® products visit our stand E42.





## MSD – B16

MSD, Hertford Road, Hoddesdon, Herts EN11 9BU

TEL: 01992457272

WEBSITE: [www.diprobahcpc.co.uk](http://www.diprobahcpc.co.uk)

EMAIL: [ellen.edwards@merck.com](mailto:ellen.edwards@merck.com)

CONTACT NAME/S: Ellen Edwards

The Diprobase emollient range has been patient friendly for 30 years. The formulations are tried and trusted making it the UK's number 1 most GP prescribed emollient. Diprobase is an MSD – Consumer Care product. Today's MSD is a global healthcare leader working to help the world be well. MSD is a trademark of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.

## Novartis Pharmaceuticals UK Ltd – C30

Novartis Pharmaceuticals UK Limited

UK Head Office, Frimley Business Park Frimley, Camberley Surrey GU16 7SR

TEL: +44 1276 692255

WEBSITE: [www.novartis.co.uk](http://www.novartis.co.uk)

EMAIL: [Richard.bleby@novartis.com](mailto:Richard.bleby@novartis.com)

CONTACT NAME/S: Richard Bleby / Danika Douglas

Novartis UK is the UK affiliate of Swiss-based Novartis AG.

Novartis conducts research into many different disease areas, including dermatology. Building on its heritage as an innovator in healthcare solutions, Novartis Specialty Dermatology is developing science-driven therapies to redefine treatment paradigms and transform patient care.

## Pern Consumer Products Ltd – B1

Sales, Marketing & Customer Services, 13a Station Street, Cockermouth CA13 9QE

TEL: 0800 599 9022

WEBSITE: [www.dermacool.co.uk](http://www.dermacool.co.uk)

EMAIL: [marketing@pern-consumer.co.uk](mailto:marketing@pern-consumer.co.uk)

CONTACT NAME/S: Phil Richardson, Dee Malia-Richardson

Pern Consumer products are featuring Dermacool - Menthol in Aqueous Cream, available in a new 5% strength (plus 0.5%, 1.0% & 2.0% strengths). Also introducing their new 500g pump dispenser (all strengths) plus the new 5% 20g & 100g tubes. Also ask Pern about the launch of SLS Free Dermacool

## Pierre Fabre Dermo-Cosmétique – B14

Pierre Fabre Ltd, 2 Imperial Place, Borehamwood, Hertfordshire WD6 1JN

TEL: +44 (0)208 731 3333

EMAIL: [pfdc@pierre-fabre.co.uk](mailto:pfdc@pierre-fabre.co.uk)

CONTACT NAME/S: Melanie Black

Pierre Fabre is a leading French pharmaceutical laboratory. Alongside our prescription products, we market well known skin care brands including Eau Thermale Avène for sensitive & allergic skins. After 12 years of research, we are delighted to announce the launch of XeraCalm A.D. the first patented, biotechnological active ingredient to treat eczema-prone skin.

## RB UK Commercial Limited – E21

Wellcroft House, Wellcroft Road, Slough, Berkshire, SL1 4AQ

TEL: 01753 506687

EMAIL: [Aisha.Walton@rb.com](mailto:Aisha.Walton@rb.com)

CONTACT NAME/S: Aisha Walton

Reckitt Benckiser is a global company operating in health & personal care. The UK healthcare business has leading pharmaceutical products, including E45 Cream for the relief of eczema and dry skin conditions.

## Roche Products Ltd – D20

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Herts AL10 9JU

TEL: +44 (0)1707 366000

WEBSITE: [www.roche.co.uk](http://www.roche.co.uk)

EMAIL: [georgina.wardell@roche.com](mailto:georgina.wardell@roche.com)

CONTACT NAME/S: Bryan Richardson, Georgina Wardell, Nicola Forster

## Schuco – E34

Axis 4, Rhodes Way, Watford WD24 4YW

TEL: 01923 234 600

WEBSITE: [www.schuco.co.uk](http://www.schuco.co.uk)

EMAIL: [sales@schuco.co.uk](mailto:sales@schuco.co.uk)

CONTACT NAME/S: Kirsty Dungate

Established in 1957 Schuco has a commendable heritage supplying innovative medical devices and services throughout the healthcare industry. At Schuco our experts have a passion and expertise in dermatology and medical aesthetics. This expertise combined with our new training academy ensures that our customers receive superior product support and continued education.

## SkinCeuticals – B50b

SkinCeuticals, L'Oréal UKI Ltd, 255 Hammersmith Road, London W6 8AZ

TEL: UK: 0800 028 2331 ROI: 1890 812 740

WEBSITE: [www.skinceuticals.co.uk](http://www.skinceuticals.co.uk)

EMAIL: [contact@skinceuticals.co.uk](mailto:contact@skinceuticals.co.uk)

CONTACT NAME/S: Jane Toner, Claire Marlow, Belinda Aloisio, Suzanne Grant, Melanie Gravel

Our mission is to improve skin's appearance. Dedicated to this purpose, we make one simple promise - to provide advanced skincare backed by science. Our line of innovative, professional skincare products are designed to help prevent future damage, protect healthy skin, and correct the visible signs of previous skin damage.

## Sobi Ltd – C1

1 Fordham House Court, Newmarket Road, Fordham, Cambridgeshire CB7 5LL

TEL: 01638 722380

WEBSITE: [www.sobi-uk.co.uk](http://www.sobi-uk.co.uk)

EMAIL: [mail.uk@sobi.com](mailto:mail.uk@sobi.com)

CONTACT NAME/S: Anne-Marie Drummond

Sobi is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focussed on inflammation and genetic diseases, with three late stages biological development projects with haemophilia and neonatology. We also market a portfolio of speciality and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and companies.

## Special Interest Groups – E16

Willan House, 4 Fitzroy Square, London W1T 5HQ

TEL: 020 7391 6358

EMAIL: [conference@bad.org.uk](mailto:conference@bad.org.uk)

WEBSITE: [www.bad.org.uk](http://www.bad.org.uk)

## Spectrum – D26

35 The Avenue, Branksome Park, Poole, Dorset BH13 6LJ

TEL: 01202 761198

WEBSITE: [www.lipotripsy.com](http://www.lipotripsy.com)

EMAIL: [info@lipotripsy.com](mailto:info@lipotripsy.com)

CONTACT NAME/S: Jim Westwood

Spectrum is the exclusive distributor for Lipotripsy, a clinically proven non-invasive treatment for cellulite and body shaping.

Latest addition is the Lipotripsy Face treatment, promoting cell renewal, improving skin density / elasticity with reduced wrinkle depth.

A popular choice for leading clinics and MediSpas wanting reliable results and high client satisfaction.

## Spirit Healthcare Ltd – A14

Spirit House, Selbury Drive, Oadby, Leicester LE2 5NG

TEL: 0116 286 5000

WEBSITE: [www.spirit-healthcare.co.uk](http://www.spirit-healthcare.co.uk)

EMAIL: [angelinat@spirit-healthcare.co.uk](mailto:angelinat@spirit-healthcare.co.uk)

CONTACT NAME/S: Angelina Thorne

Refreshingly different healthcare solutions. Enhancing patient lives whilst delivering real NHS value. Talk to us about Ameluz® our ALA nano-emulsion photosensitising agent, the BF-RhodoLED Lamp and the possibility of Community Dermatology using Ambulight our unique ambulatory light source for the PDT treatment of NMSC.

## Stiefel a GSK Company – B20

GlaxoSmithKline, Iron Bridge Road, Stockley Park West, Uxbridge UB11 1BT

TEL: 07850 341 294

WEBSITE: [www.stiefel.com](http://www.stiefel.com)

EMAIL: [geoff.d.holmes@stiefel.com](mailto:geoff.d.holmes@stiefel.com)

CONTACT NAME/S: Geoff Holmes

Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel's dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as a world leader in the skin health industry. To learn more about Stiefel, visit [www.stiefel.com](http://www.stiefel.com).



### **Thornton and Ross Ltd – D10**

Linthwaite, Huddersfield HD7 5QH

TEL: 01484 842217

WEBSITE: [www.thorntonross.com](http://www.thorntonross.com)

EMAIL: [brankoduric@thorntonross.com](mailto:brankoduric@thorntonross.com)

CONTACT NAME/S: Branko Duric

T+R Derma, incorporating Cetraben and Zeroderma, offers the most comprehensive choice of emollients for patients with dry skin conditions. Clinically effective, cosmetically acceptable, Cetraben helps provide patients with confidence and freedom from eczema and dry skin. Zeroderma offers similar formulations to leading brands with cost savings of up to 37%.

---

### **Typharm Dermatology Ltd – B18**

14D Wendover Road, Rackheath Industrial Estate, Norwich, NR13 6LH

TEL: 01603 722 480

WEBSITE: [www.typharm.com](http://www.typharm.com)

Typharm Ltd is a UK company that specialises in marketing a range of pharmaceutical products for the treatment of various inflammatory and non-inflammatory skin conditions. Products include Haelan Tape, a moderately potent steroid, presented in an occlusive tape for the treatment of recalcitrant dermatoses including eczema, heel and finger fissuring as well as overgranulation.

---

### **Loreal-Vichy Dermablend – B50c**

255 Hammersmith Road, London W6 8AZ

TEL: 020 8762 4000

WEBSITE: [www.dermablend.co.uk](http://www.dermablend.co.uk)

EMAIL: [asmith@uk.loreal.com](mailto:asmith@uk.loreal.com)

CONTACT NAME/S: Amy Smith / John Beirne

Vichy Dermablend is a high coverage, long hold foundation range. Originally created by Dr. N. Craigs as an extreme coverage solution for his wife's Vitiligo. Nowadays, Dermablend continues to give women confidence through high coverage, natural finish foundations suitable to cover both minor and severe skin concerns.

---

### **Wisepress Medical Bookshop – A23**

Wisepress Medical Bookshop, 25 High Path, Merton Abbey, London SW19 2JL

TEL: Phone: +44 20 8715 1812

EMAIL: [bookshop@wisepress.com](mailto:bookshop@wisepress.com)

WEBSITE: [www.wisepress.com](http://www.wisepress.com)

Wisepress are Europe's principal conference bookseller. We exhibit the leading books, sample journals and digital content relevant to this meeting. Books may be purchased at the booth, and we offer a postal service. Visit our online bookshop for special offers and follow us on Twitter for the latest news @WisepressBooks.



## VENUES


- A SECC
- B Kelvingrove Art Gallery
- C Glasgow Science Centre
- D Brian Maule at Chardon d'Or

## HOTELS

- 01 Blythswood Hotel
- 02 Campanile
- 03 Crowne Plaza
- 04 Express by Holiday Inn Theatreland
- 05 Glasgow Marriott
- 06 Grand Central
- 07 Hilton Garden Inn
- 08 Hilton Glasgow
- 09 Holiday Inn Glasgow Theatreland
- 10 Holiday Inn Express Riverside
- 11 Hotel Du Vin at One Devonshire Gardens
- 12 Ibis Hotel
- 13 Indigo Hotel
- 14 Jury's Inn Hotel
- 15 Menzies
- 16 Novotel
- 17 Park Inn By Radisson
- 18 Premier Inn Argyle Street
- 19 Premier Inn George Square
- 20 Radisson Blu

10 mins by public transport to the city centre

10 mins walk to the city centre



# General Information

## DELEGATE BAGS

The Conference & Events Department is aiming to limit the impact the Annual Meeting has upon the environment.

Conferences and exhibitions provide a huge amount of waste and this year we aim to continue to implement measures to improve this.

Following feedback from previous meetings delegates will be provided with a generic delegate bag (as illustrated). This bag is made from recycled plastic bottle and has the BAD Logo on the side.



Don't forget your bag!

We have made a decision not to include a sponsor, date or annual meeting destination. This will enable you to reuse the bag for other annual meetings as well as other BAD meetings. We hope this will become your BAD 'Bag for Life'.

If you have a bag from a previous annual meetings please bring it with you

## EVALUATION FORM

This year's evaluation form will be on-line and all attendees will be sent a link after the meeting.

Thank you in advance for taking the time to complete it, as it will help us in improving future annual meetings.

## CES MEETINGS CALENDAR

### September 2014

#### XV World Congress on Cancers of the Skin

Venue: EICC, Edinburgh

Date: 3rd – 6th September

#### Dermdoc

Venue: Willan, London

Date: 29th September

### October 2014

#### Clinical Dermatology Update

#### Meeting for Staff and Associate Specialist Doctors

Venue: Coombe Abbey, Coventry

Date: 1st – 3rd October

### November 2014

#### SpR Training Event

Venue: Indian YMCA, London

Date: 13th – 14th November

#### BCDG Annual Meeting

Venue: Willan House, London

Date: 15th November

#### The Annual UK Dermatology Course for Consultants

Venue: Hilton Paddington Hotel, London

Date: 21st – 22nd November

### December 2014

#### 7th International Congress, Psoriasis from Gene to Clinic 2014

Venue: QEIIICC, London

Date: 11th – 13th December

For Further Details on any of these meetings please contact:

Conference & Event Services, 4 Fitzroy Square, London W1T 5HQ

Email: [conference@bad.org.uk](mailto:conference@bad.org.uk) Tel: + (0)20 7391 6358



Join our facebook Group



follow us on Twitter





# Coming Soon....


## [www.bad2014app.org](http://www.bad2014app.org)

- Review agenda & speakers
- Interactive floorplans
- View abstracts & e-posters
- View sponsors & exhibitors
- Select sessions to record your own CPD




BAD are grateful to Janssen  
for their support  
of the meeting app





LD PATH GROUP



## Bringing Dermatopathology expertise direct to your practice

Premium specialist reporting services by **a team of 10 dermatopathologists, all holding substantive NHS positions / 24-48 hours turnaround / Competitive flat fee structure for up to 7 specimens** (including courier, special stains, immunocytochemistry and billing) / Second opinion from expert panel / **Reports delivered securely by email** and via SSL-encrypted website / **Frozen sections & MDM support** / Privileged access to **educational material**.

« I know that the cases I send to LDPath will be reported by genuine specialists who hold substantive NHS positions and are at the forefront of their sub-specialty. »

Dr Raj Mallipeddi, Consultant Dermatologist  
St Thomas' Hospital



### Dr Florence Deroide, MD - Partner

Consultant Dermatopathologist and Head of the Cellular Pathology Department at the Royal Free Hospital. Trained in France (Paris Ouest, Angers), more than 16 years of experience, including 10 in the UK.

Florence co-organises the Anglo-French dermatopathology meeting in London.

BAD 94th Annual Meeting  
(1st-3rd July 2014)

Meet our team at **STAND B12**



### Dr Alistair Robson BSc (Hons) - Partner FRCPath DipRCPath

Consultant Dermatopathologist for 13 years at the tertiary referral centre St John's Institute of Dermatology.

Speaker at international conferences in the US, Middle & Far East and member of the Unna Darier Dermatopathology Society.

Numerous research works presented in the last 12 months at top international forums, e.g. American Academy of Dermatopathology, British Society of Dermatopathology, World Lymphoma Congress in Berlin...

Join the 100+ clinicians already benefiting from our first class services

# 15th World Congress on Cancers of the Skin

## 3-6 September 2014

### Edinburgh, Scotland



visit  
[www.wccs2014.org](http://www.wccs2014.org)  
for details

